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Abstract 
A significant portion of the pharmaceutical expenditures in developing countries is 
wasted due to inefficiencies associated with the management of drug supplies, including 
drug selection, distribution and use. Essential drugs are the foundation for nearly every 
public health programme aimed at reducing morbidity and mortality in the developing 
world, and the pharmaceutical expenditure can account for a high proportion of the total 
health expenditure of the country. 
The main aim of the study is to evaluate the management of essential drugs in the 
public health facilities in Uganda. This is a cross-sectional study carried out in the 
districts of Kampala and Mbale employing both qualitative and quantitative methods. 
Standard outcome indicators as described in the WHO Operational Package for 
Monitoring and Assessing the Pharmaceutical Situation in Countries are adapted and 
used in this study. Data collection methods include semi-structured interviews with the 
key informants at the health facilities, review of the documents and physical inspection 
of the drug stores at the health centers. 
The study findings show an average availability of 62.5% of the key drugs in the public 
health facilities. The average stock out duration of the basket of the key drugs is 
approximately 5 months. The inventory management is generally poor with only 36% 
of the records that coincide with the physical counts of the drugs. Only 20% of the staff 
is formally trained in the drug logistic management. The study further reveals that only 
10% of the warehouses have adequate storage for the drugs. 
The stock out of drugs at the health facilities is mainly attributed to poor drug financing 
and the inefficiencies in the drug distribution chain. The inefficiencies are mainly due to 
the rampant stock outs of drugs at the National Medical Stores and the delays in the 
supplies. Poor inventory control and poorly trained staff in drug logistic management 
also contribute to the poor drug management. 
The study concludes with policy recommendations urging the government to improve 
on the monitoring and evaluation of the drug management in public health facilities. 
The study also recommends increased drug financing by the government and the 
improvement in the efficiency of the National Medical Stores in drug procurement and 
distribution. 
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CHAPTER 1: BACKGROUND TO THE STUDY 
1.1 Introduction 
A significant portion of the pharmaceutical expenditures in developing countries is wasted 
due to inefficiencies associated with the management of the drug supplies, including drug 
selection, distribution and use (Govindaraj et al 2000). To enhance the efficiency of 
pharmaceutical resources and expand access to essential drugs, countries have been 
encouraged to develop and implement the policies of essential drugs. Since the first WHO 
model of essential drugs was published in 1997, over 140 countries have adopted the 
national essential drugs list. Despite this progress, many developing countries are still 
struggling to assure access to essential drugs. The proportion reaches 50% in the poorest 
parts of Africa and Asia (Govindaraj et al 2000). 
Pecoul et al (1999) argues that essential drugs are the foundation for nearly every publ ic 
health programme aimed at reducing morbidity and mortality in the developing world, and 
pharmaceutical expenditure can account for a high proportion of the total health 
expenditure of a country. The lack of access to essential drugs or vaccines because of 
economic reasons raises new human rights issues in a world that remains divided among 
wealthy countries, developing countries, and the rest of the world (Pecoul et al 1999). 
Inadequate access to essential drugs in developing countries is also aggravated by problems 
in the pharmaceutical procurement and distribution systems (Govindaraj et al 2000). The 
causes of these problems include market failures (such as drug information), and 
government failures (associated with limited management capacity. weak management 
information systems, and poor warehouse and storage systems). The problems are 
compounded in some countries by widespread corruption in the public sector procurement 
and distribution systems, incl uding in the health sector. The inefficient use of resources in 
public procurement systems represents an important motivation for health sector reform 
efforts (Govindaraj et al 2000). 
In the area of supply and rational use of pharmaceuticals, there is still room for 
improvement. In most health systems, the potential for improving the supply process is 
tremendous, reflecting in part the magnitude of current inefficiencies and waste. Lack of 
careful selection, incorrect quantification, high prices, poor quality, theft, improper storage, 
expiration of drugs, irrational prescribing, and correct use by patients results in losses 
totaling 70% of the original expenditure. Some drug management improvements require an 
initial investment in systems development training, physical infrastructure, and other 
development initiatives. But the potential cost reductions and therapeutic improvements are 
dramatic. Even small improvements, when made in a number of related areas of drug 
management, can yield substantial overall savings (MSH 1997). 
1.2 The pharmaceutical sector in Uganda 
Uganda is a landlocked, equatorial East African country that borders the Democratic 
Republic of Congo, Kenya, Rwanda, Sudan, and Tanzania with Lake Victoria making up 
much of its southern border. Following a long period ot~ at times, violent political turmoil, 
Uganda developed a democratic constitution in 1995, and held presidential and 
parliamentary elections in 1996 and 2001 (Leach et al 2005). 
The United Nations estimates the population of Uganda at 24.2 million (2004) with 88 
percent living in the rural areas. Classified as a low income country by the World Bank, 
Uganda is also classified as a Least Developed Country by the United Nations. Per capita 
income was reported at $240 in 2003, reflecting a continuing decrease. As of 2002 
Uganda's total external debt amounted to $3.8 billion. This heavy debt service is one 
reason the country struggles to provide social services in adequate quantity and quality 
(Sachs et al 2004-1). The economy depends largely on agriculture, with 80 percent of 
Ugandans deriving their livelihoods from this sector. Currently, it is estimated that 35 
percent of Ugandans live on less than a dollar a day and are unable to meet their basic 
requirements (Leach et al 2005). 
1.2.1 The burden of disease 
Like many countries in Sub-Saharan Africa, the issue of universal access to medicines has 
taken on a renewed urgency and visibility in recent years due to the AIDS, TB and malaria 
epidemics. However, these three diseases are not the only ones confronting people in this 
or any other part of the region. Accord ing to the Burden of Disease Study in Uganda, over 
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75% of the life years lost to premature death were due to ten preventable diseases. Perinatal 
and maternal conditions (20.4%), malaria (15.4%), acute lower respiratory tract conditions 
(10.5%), AIDS (9.1%) and diarrhea (8.4%) together account for over 60% of the national 
death burden. Others at the top of the list include tuberculosis, malnutrition (with 38% of 
under-5s stunted, 25% underweight for age and 5% wasted), trauma/accident and measles 
(Ministry of Health 1999). The health indicators are poor with the Infant Mortality Rate at 
88 deaths per 1000 live births and the Maternal Mortality Ratio at 505 deaths per 1000,000 
live births (Uganda Bureau of Statistics 2001). 
1.2.2 The health system structure 
Uganda is divided into 56 districts, and the health care system is aligned to the 
administrative structure shown in Table I below. 
Table 1: Health Systems Structure 
Descrip!!on 
Village 




County as sub-district 
District 
Source: Ministry of Health. 2002 
I Health Centre I 
II Health Centre I I 
[[ I Health Centre III 
IV 
V 
Health Centre IV 
Health Centre V 
An updated (2004) health facility inventory is indicated in Table 2 below. 
Table 2: Health Facility Inventory 
OWNERSHIP 
Level of facility Government NGO Private 
Hospital 56 45 7 
HCIV 148 9 3 
HC III 706 157 10 
HC II 945 391 257 
Total 1855 600 274 
. , 







Since 1972, the number of public, non-governmental and private health facilities has 
increased by 400 percent and the population has more than doubled. In spite of this, a 1993 
inventory of health units found that geographical access to health care is limited to 49% of 
the population, i.e. population living within 5 kilometers of a health facility providing both 
curative and preventive health services. Rural communities are particularly affected 
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because health facilities are mostly located in towns and along main roads (Ministry of 
Health 2002a). 
1.2.3 The National Drug Policy 
The overall goal of the National Drug Policy in Uganda is to contribute to the attainment of 
good health for the population of Uganda, through ensuring the availability, accessibility 
and affordability at all times of essential drugs of appropriate quality, safety and efficacy, 
and by promoting their rational use. Other objectives of the National Drug Policy are to 
ensure availability of sufficient, suitable, trained pharmaceutical and other relevant staff to 
enable effective implementation of the NDP, and to optimize use of available resources, 
knowledge and expertise in the implementation of NDP through the establishment of an 
active patternship between the community, government bodies and private health providers 
involved in the pharmaceutical sector and through co-operation with regional and 
international agencies (NDP 2002b). 
1.2.4 The drug supply system 
One of the policy areas of the NDP is to establish and maintain a secure, cost-effective 
supply system in order to ensure that required essential drugs are available and accessible 
to the population and that the quality is maintained up to the point of use. This is achieved 
through timely quantification of the country's drug requirements, by maintaining constant 
availability at all levels of adequate quantities of the required essential drugs, by ensuring 
that all drugs are appropriatelY, cost-effectively and safely stored at all levels in order to 
maintain quality and minimize storage related costs and drug losses from whatever cause, 
and lastly to establish and constant availability of required essential drugs throughout the 
country (NDP 2002b). 
Prior to the establishment of the National Medical Stores in 1993. the essential drugs were 
managed by the Uganda Essential Drugs Management Programme. The Uganda Essential 
Drugs Management Programme (UEDMP) began in 1985 with the assistance of DANIDA 
and the Danish Red Cross to provide rural health facilities with essential drugs. Initially 
conceived as an emergence programme to provide stocks of basic pharmaceuticals to rural 
health facilities which had for years been without drugs, it soon became the main source of 
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drugs for the whole country. Until the introduction of the UEDMP, the government had 
only been able to provide a dozen or so of the 277 items on the essential drugs list 
(Okuonzi et al 1995). The Essential Drugs Management Programme had operational 
inefficiencies because of lack of an enabling legal framework. In order to counteract this, 
the National Drug Pol icy was enacted in 1993 (National Drug Pol icy and Authority Statute 
1993). 
Consequently upon the establishment of the National Drug Policy, the National Medical 
Stores (NMS), which is an autonomous drug supply agency, responsible for supplying 
drugs to public health facilities was created. The institutional role and responsibility of the 
National Medical Stores for the public sector drug procurement and supply, was for the 
first time, formalized through signing of a memorandum of understanding between the 
ministry of health and the National Medical Stores in 2003. To improve efficiency of the 
drug supply system, the new "Pull" system was introduced country-wide in January 2003 
to replace the essential drugs kit (PUSH system). The "Pull" system is a demand based 
ordering system where, the credit lines were linked to a logistic system that included 
scheduled ordering and delivery (Ministry Of Health, 2004a). Despite all these initiatives 
fore mentioned, problems still remain in the areas of drug management in the public health 
facilities. 
1,3 Problem statement 
In order to improve access to essential drugs at the public health facilities in Uganda, there 
has been an increased budgetary allocation for drug procurement by the government. In 
addition, the pull system was adopted with the hope of improving the availability of drugs 
at the health facility level which would also translate into improved access to drugs and 
utilization of the pub I ic health faci I ities. 
However, challenges still exist. Routine monitoring and surveys have established irregular 
drug procurement and below target expenditure on drugs compared to the indicative cash 
budget. This falls far below 50% of the Primary Health Care Conditional Grant Guidelines, 
medicines expenditure. This state of affairs is attributable to re-allocation of funds, 
irregular ordering, and! or sub-optimal service level at National Medical Stores. In addition, 
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some districts and hospitals and hospitals were found to be purchasing from the private 
sector. This brings into question the issues of value for money and also the quality of the 
products being procured (Ministry of Health, Uganda 2004a). 
Apart from the problems of financing, the public drug supply system in many countries 
including Uganda continues to be plagued by ineffective management systems, lack of staff 
incentives, inability to control fraud and abuse, political pressures that channel drug 
supplies to better off areas, and inefficient drug selection and use (MSH 1997). Therefore, 
effective drug management is a prerequisite to improve access to essential drugs at public 
health facilities which is the main focus of this study. 
1.4 Rationale and justification of the research 
Given the evidence of persistent poor drug management in public health facilities, the 
search for an effective drug management system remains a key concern in Uganda. It is 
hoped that the results of this study will reveal where some of the major problems lie. This 
should enable the policy makers to take the relevant corrective measures and avert the 
chronic problem of drug mismanagement and misallocation of public resources. 
1.5 Aim and objectives of the study 
The aim of the study is to evaluate the management of essential drugs in the public health 
facilities in Uganda. 
/.5.1 Specific objectives of the study are to: 
i. Find out whether the key essential drugs are always available at the health facilities 
and if not, establ ish the major causes. 
II. Establish the average time period in which the key drugs at the public health 
facilities are out of stock and the average time between requisition and delivery of 
the drugs (lead time). 
III. Explore whether the drugs at the health facilities are safe, and of good quality. 
iv. Find out whether effective inventory control systems are in place; establish levels of 
qualification of staff in charge of drug stores and the suppliers of drugs. 
v. Suggest ways of improving drug management at the public health facilities. 
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1.6 Outline of the dissertation 
The dissertation is structured as follows: 
In Chapter 2, the theoretical and empirical literature review is presented. This mainly looks 
at the drug supply, the essential drug concept and the factors that affect access to the 
essential drugs. It also looks at studies carried out on drug management in different 
countries. 
(n Chapter 3, the conceptual framework for analyzing the drug management at the public 
health facilities is presented. This is followed by the methods used to obtain the data and 
the methodology for analysis. 
Chapter 4 presents the findings of the study. Both quantitative and qualitative data for each 
of the pharmaceutical indicators used in this study are presented. The results are 
summarized in tables and graphs. 
The key findings concerning the drug management are discussed in Chapter 5. The 
implications for the observed trends and the explanations are also given. 
Finally, Chapter 6 offers conclusions from the study followed by policy recommendations, 
which spell out the different alternatives that can be pursued to improve the drug 
management at the public health facilities in Uganda. 
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CHAPTER 2: LITERATURE REVIEW 
2.1 Introduction 
This chapter describes the theoretical underpinnings that guided the study, and also 
discusses other studies carried out on the same topic in other countries. It also looks at the 
literature that was useful in drawing up the methodology and enabled the researcher to 
make informed discussions and recommendations. The drug management cycle, the 
concept of essential drugs and the access to essential drugs in developing countries is also 
reviewed. 
2.2 Public health objectives and essential drugs concept 
Public health is concerned with using available resources to achieve maximum health 
improvements for the population. The perspective is not that of the individual patient, who 
may well benefit from a costly drug, but of the entire community or population, which 
benefit, if safe and effective drugs are accessible to all who need them. In 1975, WHO 
defined essential drugs as "indispensable and necessary for the health needs of the 
population. They should be available at all times, in the proper dosage forms, to all 
segments of the society". And in 1978, the WHO conference at Alma Ata recognized 
essential drugs as one of eight elements of primary health care (MSH 1997). 
Essential medicines are those that satisfy the priority health care needs of the population. 
They are selected with due regard to public health relevance, evidence on efficacy and 
safety, and comparative cost-effectiveness. Essential medicines are intended to be available 
within the context of functioning health systems at all times in adequate amounts, in the 
appropriate dosage forms, with assured quality and adequate information, and at a price the 
individual and the community can afford. The implementation of the concept of essential 
medicines is intended to be flexible and adaptable to many different situations; exactly 
which medicines are regarded as essential remains a national responsibly. Careful selection 
of a limited range of essential medicines results in a higher quality of care, better 
management of medicines (including improved quality of prescribed medicines), and more 
cost-effective use of health resources (WHO 2002a). 
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The WHO Model List of essential Medicines has been updated every two years since 1977. 
The Model List and its procedures are meant as a gu ide for the development of national and 
institutional medicine lists. Most countries have national lists and some have provincial or 
state lists as well. National lists of essential medicines usually relate closely to national 
guidelines for clinical care practice which are used for the training and supervision of 
health workers. Lists of essential medicines also guide the procurement and supply of 
medicines in the public sector schemes that reimburse medicine costs, medicine donations, 
and local medicine production (WHO 2002a). 
As a model product, the WHO Model list aims to identify cost-effective medicines for 
priority conditions, together with the reasons for their inclusion, linked to evidence-based 
critical guidelines and with special emphasis on public health aspects and considerations of 
value for money. The core list presents a list of minimum medicine needs for a basic health 
care system, listing the most efficacious, safe and cost-effective medicines for priority for 
priority conditions. Priority conditions are selected on the basis of the current and estimated 
future public health relevance, and potential for safe and cost-effective treatment (WHO 
2002a). 
The World Health Organization (WHO) has promoted the concept of essential drugs to 
advance health equity through expanded access to basic medicines for the poor in poor 
countries (Reich 2000). The essential drug list is mainly composed of generic drugs which 
have a potential advantage over the branded ones in terms of prices. Generic drug 
programmes are today the most relevant economic strategy for drug supply. The most 
important economic feature of generic drugs, unlike the situation with named brands, is that 
they allow for competition among the producers of a given drug (Antezanna et al 996). 
Competitive bulk procurement by generic name is a central feature of most essential drug 
programmes as well as many large hospitals and health services in high income countries 
(Bennet et aI1997). Generic drug prices in well developed European markets are more 
typically 60-70% of brand prices (Balance 1992). The prescription, dispensing, and even 
substitution that is promoted in many countries allows for significant cut in the cost of 
drugs and health services. 
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In order to be consistent with a public health perspective, the implementation of the 
essential drug concept the adoption of national drug policies and through practical drug 
management improvements which requires total government commitment 
2.3 The drug logistics system 
The drug logistics system is the system responsible for ensuring that drugs move from 
where they are manufactured to the intended user that is the patient or the cl ient. It involves 
activities such as transportation, storage, maintaining adequate supplies and keeping 
accurate records of drugs. Different personnel manage the various aspects of the logistic 
system, but the overall objective is to ensure that drugs are available at service delivery 
points at all times and that these drugs are the right amount, of good quality, and the 
essential drugs needed by the particular community being served (MSH 1997. Ministry of 
Health 2002c). 
The drug logistic system is part of the drug management cycle, which is built around four 
pillars namely: selection, procurement, distribution and use. Each of the major pillars 
builds on the previous function and leads logically to the next (MSH 1997, Ministry of 
Health 2002c). The supply and management of drugs is a continuous process that is 
illustrated in Figure I below. 
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Source. MSH, 1997 
The selection of drugs involves deciding on the list of drugs to satisfy the health care needs 
of the majority of the population. To select the most appropriate drugs, selection teams 
depend on the current information on common illnesses, budget limits and pharmaceutical 
advances, as well as on input from health workers. In this way, contributions from the 
procurement, distribution and use of the components of the cycle inform the selection 
process and keep the drug management cycle in motion. Also selecting the most useful 
drugs avoids wasting scarce resources on unnecessary, unsafe or ineffective drugs (MSH 
1997, Ministry of Health 2002c). Most small countries generally base their drug 
requirements on past consumption as data on drug utilization and morbidity are usually 
lacking (WHO 2002c). 
Procurement is the process of acquiring drugs from private or public suppliers. Drug 
availability and costs are very much dependent on the effectiveness of a procurement 
system. Strong procurement processes ensure that selected drugs are purchased at 
reasonable prices, are of acceptable quality and in the right quantity. Procurement strategies 
vary widely, but most models include the following critical activities; drug needs 
quantification, bid management, supplier selection and drug qual ity assurance (MSH 1997). 
I I 
The distribution process begins when drugs are sent from the manufacturer or supplier and 
ends when the drug consumption information is sent back to the procurement unit. An 
effective distribution system is the cornerstone of the drug logistics management. Such a 
system should not only maintain constant supply of drugs but also: 
• keep the drug in good condition throughout the distribution process; 
• minimize losses due to spoilage and expiry; 
• maintain accurate records; 
• reduce theft and fraud; and 
• provide information for forecasting future drug needs. 
When distribution systems function well and are supported by good procurement practices, 
patients are more likely to receive the necessary drugs on time and in good condition. The 
best systems are probably based on a combination of public and private management. For 
example, the transport of drugs and supplies can often be done better by private transport 
companies. In all cases, distribution and storage should be monitored to ensure the quality 
of drugs at all levels of the distribution network (WHO 2002b, Ministry of Health 2002c). 
[mplementing best practices in inventory management can improve overall service levels 
and reduce costs in the drug supply chain. Two methods stand out, which, which are 
defined by the level of the supply chain that orders drugs. In a pull system, each level of the 
supply chain determines the drugs and the quantity to be ordered by using the formula that 
considers demand patterns, distribution frequencies, costs, inventory levels and other 
relevant factors. This is preferred method because it allows more flexibility and orders are 
sent based on real consumption data. [n a push system, a higher level in a supply chain 
determines the drugs and their quantity. This approach is only recommended in relief 
situations when there is insufficient lower lever staff to determine orders (Kearney Inc. 
2004). The drug trucking study carried out in Uganda in August 2002 indicated sub-
optimal levels of drug procurement at the Health Sub-District (HSD) level. There were also 
significant performance differences between the HSDs depending on the procurement 
system adopted at the district level and the logistic management capacity at the HSD level. 
[n the new pull system, the credit lines were linked to a logistic system that included 
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ordering and delivery. The new pull system was introduced country wide in January 2003 
to replace the essential drug kits (Ministry of Health 2003a). 
Additionally, other inventory management techniques must be handled, including defining 
stock records, selecting items to be stocked, maintaining a balance between service levels, 
and adopting a model for re-ordering medicines (Kearney Inc. 2004). An appropriate 
supply interval is determined depending on which choice is made between the push and 
pull systems. This will determine whether deliveries are made to user units quarterly, 
monthly, weekly or at any other time. If deliveries are made weekly, average stock levels 
will be low and the likelihood of stock outs will decrease, but transport costs will be high. 
If deliveries are made only once a year, transport costs will be so low, but the average 
stocks and storage costs will be high. The optimum re-supply interval needs to be worked 
out to suit individual programme needs. Most public programmes use intervals of one to 
three months (MSH 1997). 
A prerequisite to adequate supply of medicines requires skilled people who are trained to 
manage the procurement process. These people, working from a central office must have a 
keen understanding of all aspects of the purchasing process and know how to prioritize 
medicines based on budgetary restrictions. In addition doctors and pharmacists must be 
able to develop an accurate demand forecast and manage inventory levels to ensure 
availability of drugs the various consumption points. Unfortunately, given the high 
turnover of personnel in many organizations, it is a challenge to hire and retain people with 
these skills. This is particularly problematic in developing countries where health managers 
are assigned through political networks. These people are not evaluated based on their 
performance and have little incentive to strive for efficient resource management (Kearney 
Inc. 2004). 
Further more, incentives and performance measures, when used effectively, can encourage 
employees to act in the best interest of the patient. The World Health Report 2000 defines 
incentives for health workers as "all the rewards and punishments providers face as a 
consequence of the organizations in which they work, the institutions under which they 
operate, and the speci fie interventions they provide" (WHO 2000b). Health workers face a 
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hierarchy of incentives or disincentives generated by the work they do, the way they are 
paid, and the organizational and system context in which they work. Typically, incentives 
vary by type of employer: nongovernmental organization, public, or private. Pubic sector 
incentives tend to be the weakest because of resource constraints and bureaucratic rules on 
civil servant employment constrain the use of both financial and non-financial incentives 
(Hongoro et al 2003). If at all possible, positions that demand specific knowledge of 
medicine supply chains should be filled with professionals who have an academic 
background and experience in this area. These professionals should be evaluated on their 
performance based on a mix of indicators which include maintaining high service levels 
and achieving saving targets to managing budgets and should be rewarded for their efforts. 
In addition, information technology can be valuable in managing the supply of medicine, 
particularly tools that are designed to support more strategic and long-term supply chain 
decisions. For example, the more sophisticated applications on the market today permit 
administrators to evaluate different supply chain network scenarios that balance cost 
reduction with improving service levels. Other applications help optimize the number of 
deliveries and manage the daily distribution of medicines. These tools to integrate the 
needs of each hospital or health center while compensating for the restriction of the drug 
supply chain (Kearney Inc. 2004). 
The logistic system delivers the correct drugs to the service delivery points. However, 
efforts in selection, procurement and distribution would be wasted if the drugs are not used 
rationally. Rational use of medicines is crucial to securing the effectiveness of a country's 
drug supply and is one of the best sources of saving in the medicine supply chain. Rational 
drug use requires that patients receive medications appropriate to their clinical needs, in 
doses that meet their individual requirements. for an adequate period of time, and the 
lowest cost for them and their community. Rational use of drugs promotes quality of care 
and cost-effective therapy. It helps to ensure that drugs are used only when they are needed, 
and that people understand what the medicines are for and how to use them. Policies to 
promote rational drug use need to address the prescribers, dispensers and consumers of 
drugs as well as manufactures and sellers, and traditional healers. All these actors have an 
import influence on how drugs are used. A variety of strategies and interventions are 
needed to influence drug use (WHO 2002b). 
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2.4 Access to essential medicines in developing countries 
Access to medicines has taken a central debate in the international policy debate. It is 
increasingly viewed as a basic human right, which is evident in the light of the HIV/ AIDS 
crisis that is devastating populations in the developing world, most accurately in Sub-
Saharan Africa where as many as 29 million persons are infected with HIV/AIDS 
(UNAIDS and WHO 2002) and as little as 5 to 6 percent of the population currently have 
access to the medicines they need (Moatti et al 2002). 
The Working Group on Access to Essential Medicines incorporated the WHO definition 
that provided the basis for the Millennium Development Goals indicator used to assess 
access: the proportion of the population with access to affordable, essential drugs on a 
sustainable basis is the percentage of the population that has access to a minimum of 20 of 
the essential drugs (Leach et al 2005). Access is defined as having drugs continuously 
available and affordable at public or private health facilities or drug outlets that are within 
one hour's walk of the population (WHO 1999). 
Despite the progress in the last decades, the likelihood of a person having access to 
essential medicines is still affected greatly by that person's income level. The World's 
Medicines Situation found that people in poorer countries were much less likely to have 
access to these medicines was living in low-income countries. This is a disproportionate 
share of the global burden, given their estimates that low income countries account for 
approximately 60 percent of the world's population (WHO 2004). According to WHO, in 
1999, roughly 80 percent of the global population without access to medicines was living in 
low income countries. In contrast, only 0.3 percent of those lacking access to essential 
medicines lived in high income countries, which account collectively for about 15 percent 
of the world's population. In global context, that 15 percent of the world's population 
consumes 91 percent of the medicines produced (WHO 2000). Of people living in low-
income countries, nearly 40 percent did not have access to essential medicines in 1999 
(WHO, 2004). 
Geographically, the lack of access to essential medicines is especially severe and 
concentrated in A frica and India. In fact, 38 percent of people without access to essential 
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medicines live in India. Another 15 percent of the people without access live in African 
countries (WHO 2004). Together, India and Africa account for 53 percent of the world's 
population without access to essential medicines. Although the disease burden and 
mortality from preventable or curable illness is highest in African countries, pervasive 
poverty means that the continent's share of the global pharmaceutical market is slightly 
more than I percent (Leach et al 2005). 
The lack of access to medicines throughout large proportions of the populations of most 
developing countries reflects both the lack of sufficient incentives for developing new 
medicines to target the communicable diseases that disproportionately afflict the poorest 
countries, as well as the inability to pay for and effectively distribute those that do exist. 
The result is what the U.K. government has called a "mismatch between pharmaceutical 
needs in developing countries and the current nature of the pharmaceutical market" (DFI D 
2004). 
2.5 Barriers to access to essential medicines 
The Working Group on Access to Essential Medicines pointed out six of the most 
important barriers to access. Inadequate national commitment to making healthcare a 
priority from the national to local levels remains one of the greatest barriers to increasing 
access to existing medicines. There are many reasons for this lack of prioritization. Key 
among them are lack of pol itical wi II by pol icy makers to make needs of the poor a priority; 
donor programs that can skew or limit national governments' abilities to set health policy; 
debt servicing and conditional ity for loans from international financial institutions that can 
further limit government responsiveness to basic social service needs of citizens; and 
unfortunately, the threat of corruption that continues in the healthcare sector at all levels 
(Leach et al 2005). 
Cohen (2003) argues that corruption in any of the critical decision points In the 
pharmaceutical system can be detrimental to a country's ability to improve the health of its 
population by limiting access of the population to high quality medicines and thereby 
reducing the health gains associated with proper use of pharmaceuticals (Cohen 2003). 
16 
Providing health facilities with drug and medical supplies is a very complex process that 
involves a large variety of actors from both the private and public sectors. Government 
health ministries often lack the management skills required to write technical 
specifications, supervise competitive biding, and monitor and evaluate the contract 
performance. Corruption can occur at any stage of the process and influence decisions on 
the model of procurement (direct rather competitive), on criteria the type and volume of 
procured, and on specifications and selection criteria ultimately compromising access to 
essential quality medicines. Common corrupt practices in the procurement process include 
collusion among bidders resulting in higher prices for purchased medicine, kickbacks from 
suppliers and contractors reduce to reduce competition and influence the selection process, 
and bribes to public officials monitoring the winning contractor's performance. All these 
lead to cost overruns and low quality. Other forms of abuse, fraud and mismanagement can 
occur due to insufficient and monitoring capacity. In some cases, supplies do not meet the 
expected standards, or they are only partially delivered or not delivered at all. In a context 
where quality controls are difficult to exercise, an increasing lack of funds results in 
opportunities to sell low quality, expired, counterfeit and harmful drugs at cheaper prices. 
Corrupt procurement officers can also purchase sub-standard drugs in place of quality 
medicines and pocket the difference (www.u4.noithemes/healthmedicalsllpplies.cfm). 
Due to under-financed and badly managed systems, poor record keeping and ineffective 
monitoring and accounting mechanisms, large quantities of drugs and medical supplies are 
stolen from central stores and individual facilities, and are diverted for resale for personal 
gain in the private practices or on the black market (Ferinho et al 2004). This involves a 
variety of practices such as record falsification, dispensing drugs to "ghost patients", or 
simply pocketing the patients' payment (Vian 2002). Patients are directly affected in this 
process as they are forced to supply their own medication or, in the case of hospital in-
patient stays, linens and food. This results in considerable leakage of public resources. 
Analyzing data from health centers in Uganda, McPake et al (1999) estimated that over two 
thirds of drugs meant for free distribution through the public sector was lost due to theft 
and leakage (McPake et al 1999). Distributing medical supplies to the health care facilities 
also involves managing an effective transportation system and preventing misappropriation 
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of fuel and vehicles for private on non-health related uses 
(www.u4.no/thcmes/healthmedicalsupplies.cfm). 
Inadequate human resources for health, including pharmacists and pharmacy technicians, is 
a growing problem that, if unaddressed, threatens to undermine all the efforts to strengthen 
health systems and improve health care in much of the developing world. Education, 
information, and in-service training remain potent tools to change that situation. More 
needs to be done to identify what is needed to retain skilled workers, especially in the face 
of mounting demands for health workers, such as nurses and pharmacists in the developed 
countries (Leach et al 2005). 
Furthermore, the international community has not provided adequate finance nor 
consistently fulfilled its existing promises to developing countries. Some proposed actions 
have not been carried out at all and others have not been carried out effectively. There is 
need for increased levels of long-term financial support from the world community. It 
remains an unfortunate ongoing reality that some of the world's wealthiest countries 
remain the farthest from achieving their longstanding commitment to the development 
assistance target of 0.7 percent of the gross domestic product (Leach et al 2005). 
Lee et al (1993) argues that drugs are not available to the majority of the population 
because of amongst other problems. inadequate financial resources (Lee et al 1993). 
Indeed, the overall health spending in the least developed countries is very low, even 
reaching US$2 per capita per year in some such nations. Thus for the poorest countries, 
there are no resources available domestically to support access to quality health care for 
their populations (Bale 2001). In addition, many poor nations cannot afford to buy essential 
drugs for their people, since governments are already over burdened with foreign loans 
from the International Monetary Fund and World Bank. Since drug companies invest 
heavily in research and would like to recover their cost with profit, many of the newly 
discovered formulations become prohibitively expensive for poorer countries (Pecoul et al 
t 999, Nambiar 2003). 
In Uganda, a five year National Pharmaceutical Sector strategic Sector Plan for fiscal 2003-
07 has been developed. The overall per capita minimum expenditure for basic healthcare 
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provision is estimated to be US$ 28 per person. Current spending is expected to be a small 
fraction of this. Funding for medicine in 2003/03 was US$ 1.20 per capita, which is only 
one-third of the estimated US$ 3.5 per capita needed (excluding the pentavalent vaccine 
that is currently donated and anti-retrovirals). The midterm review concludes that this 
shortfall poses a serious threat to sustained availability of essential medicines and health 
supplies and hence to the delivery of the Uganda National Minimum Healthcare Package 
(Caines et al 2003). 
Also a persistent lack of coordination of international aid reduces access to medicines. 
Most poor countries will require significant donor funding to achieve universal access to 
essential medicines. They will also need much better aid coordination to avoid 
unnecessarily heavy reporting requirements and to avoid resource-wasting duplication of 
efforts. Sectorwide approaches should be used to promote improved coordination. Donors 
should commit aid that strengthens existing systems that are proactively target the poorest 
and rural areas, and avoids vertical programming by disease or by a given donor (Leach et 
aI2005). 
Another factor which complicates further the inadequate access to drugs is that of weak 
health structure: in rural areas even the access to medical centers is limited and selective 
(Cohen 2003 and Bapna et al 1989). There are two major types of health facilities in most 
developing countries: referral hospitals and primary health care centers. Normally, patients 
are expected to visit their nearest Primary Health Care centers from where they may be 
referred to a referral hospital, which is generally situated in a more urbanized area. 
However, due to an inadequate and irregular supply of medicines to primary heath care 
centers, referral hospitals are often overloaded. For example, most drugs in developing 
countries are diverted to urban areas, regardless of the fact that most inhabitants of these 
countries live in rural areas. This overloading of referral hospitals is one of the commonest 
malfunctions of health services in developing countries (Bapna et al 1989). 
Another area that needs some scrutiny is the implementation of intellectual property rights. 
With large companies holding on to their patent rights, poorer nations cannot manufacture 
these medicines more cheaply by themselves, even if they have the resources. Prices could 
19 
be lowered if the current rules awarding the original patent holders were relaxed and many 
drug policies deregulated (Wiedenmayer 2004). 
The current incentive structure is inadequate to promote research and development of 
medicines and vaccines to address priority health problems of developing countries. For a 
number of the most neglected diseases (such as African trypanosomiasis, Chaga disease, 
leishmaniasis, and dengue fever), which primarily occur in developing countries, new 
medicines need to be developed (WHO and IFPMA 2001). For others, new medicines are 
needed to address shortcomings of existing treatments, such as safety, efficacy, appropriate 
dosing, length of treatment, and the ongoing threat of drug resistance. Despite progress in 
funding research and development (R&D) for new medicines for neglected diseases, with 
notable contributions from philanthropic foundations and some governments and 
pharmaceutical companies, more financial resources need to be mobilized in a sustainable 
way to create a strong and sustainable pipeline of new products (Leach et al 2005). 
2.6 Strategies to promote access to essential drugs 
Since the issues surrounding barriers to access have many causes, a single solution to 
improving the provision of medicines cannot be expected to succeed; it must be 
complemented by others. What this means is that every developing country should have an 
overall medicines policy and strategy founded on the essential medicines concept. The aim 
of such a policy has been succinctly defined as existing to ensure that "safe" and effective 
drugs of good quality are available and affordable to the entire population and that they are 
rationally used" (World Bank 1993). 
National medicines policy cannot succeed in isolation from broader health policies and 
government policies in general. A ministry of health is unlikely to succeed in this area 
unless it has clear and acceptable understandings reached with other government 
departments dealing with such matters as finance; and practices regarding trade, taxation, 
and customs duties, all of which are likely to have a positive or negative impacts on the 
supply of medicines (Leach et al 2005). 
Regular availability of drugs in health care facilities is a basic component of a well 
functioning health system from the perspective of policy makers and providers. It has been 
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shown that cost recovery accompanied by a fair supply of essential drugs and by better 
motivated staff improved the efficiency of the health system in Cameroon (Audibert et al 
2000). The use of market mechanisms is often advocated as means to improve public sector 
efficiency (World Bank 1993). Promotion of the private sector may be seen as means to 
bring extra funds into the pharmaceutical sector and to improve the availability of drugs 
(Bennet et al). Today, countries such as Benin, Columbia, Guatemala, South Africa and 
Thailand have developed different combinations of public and private centralized and 
decentralized approaches to drug supply (Quick 2003). 
2.7 The WHO survey package for monitoring and assessment of country 
pharmaceutical situation 
It is important for governments in developing countries to implement more effective drug 
procurement systems in order to guarantee regular access to good quality essential drugs. 
Monitoring of drug use provides important information as to whether access to drug 
planning and strategies are satisfactory or whether they need to be modified or even 
reworked. Monitoring is therefore crucial to successful implementation of national drug 
policies, programs and strategies and to achieving a rational use of quality drugs. 
In order to facilitate this process, a WHO survey package to facilitate monitoring and 
assessment of country pharmaceutical situations was developed in 2002. It provides cost-
effective means of determining availability of essential drugs, the safety, efficacy, and 
quality of medicines and whether they are used regularly. The package includes structural, 
process and outcome indicators (Brudon et al 1999). 
In this study, only some of the outcome indicators were used. They provide quantitative 
information on the achievements of the four objectives of the National Drug Policy, which 
are; availability, affordability, quality and the rational use of drugs. These indicators 
measure the degree to which these objectives are being attained (Brudon et al 1999). 
The outcome indicators do not provide information why results are good and bad; this 
could partly be obtained through the analysis of the structural and process indicators. It is 
reasonable to assume that if good results on the process indicators, then the outcome 
indicators should also show positive results or improvement over time. If outcome 
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indicators provide evidence on significant problems, when the structural and process 
indicators show good results, then decision makers should undertake a careful analysis of 
the problems, to identify causal factors and revise strategies accordingly. These outcome 
indicators are measured by percentage or Figure based on information available at the 
central level and or obtained through surveys. The indicators can be used for assisting 
national and international decision makers in measuring the results of policies and 
implementation strategies. They can also be used in comparing pharmaceutical policies of 
different countries (Brudon et al 1999). 
By the end of 2002, the WHO survey package had been field tested in 16 countries 
representing all six WHO regions. Use ofthe package in Bulgaria, revealed that availability 
of key essential medicines was high and had increased since 1995. It further revealed that 
less than 50% of the medicines prescribed were on Bulgaria's essential medicines list and 
this requires improved rational use of drugs. In the Philippines, it was revealed that the 
availability of essential drugs in rural health facilities had gone down possibly due to 
decentralization of health care services (Asamoa-Baah et al 2002). 
In Africa, field-testing of the monitoring package was carried out in Ghana, MaiL Nigeria, 
Tanzania, and Uganda. In Uganda, the Ministry of Health in collaboration with WHO, 
carried out a baseline survey to assess Uganda's pharmaceutical situation. In terms of 
access, the situation assessment revealed that availability of key medicines varied nearly 
two fold public health facilities and five-fold among district warehouses (Asamoa-Baah et 
al 2002, Ministry of Health 2002). In Tanzania, use of the household survey showed that 
households are most likely to self medicate and use public health facilities, and use of 
public health facilities is not confined to lower economic groups. More than 50% of the 
lowest economic group could not obtain all the medicine they needed (Asamoa-Baah et al 
2002). 
In addition, a study to evaluate access to essential medicines was carried out in Malaysia. 
The methodology used was adopted from the World Health Organization study protocol. 
Access was measured in terms of the availability and affordability of essential medicines, 
especially to the poor and in the public sector. The first survey in the public health clinics 
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and public district drug stores gathered information about current availability of essential 
medicines, prevalence of stock-outs and affordability of treatment (expect drug stores). The 
second survey assessed affordability of treatment in public health clinics and private retail 
pharmacies. The results revealed that the average availability of key medicines in the 
public health clinics for the country was 95.4%. The average stock-out duration of key 
medicines was 6.5 days. However, average availability of key medicines in the public 
district drug stores was 89.2%; with average stock-out duration of 32.4 days. Medicines 
affordability for public health clinics was 1.5 weeks salary and for the private pharmacies 
3.7 weeks salary. The study concluded that the majority of the population in Malaysia had 
access to affordable essential medicines (Saleh et al 2005) 
2.8 Other international related studies in the same field 
In Kenya a study to find out the availability of antimalarials in government and mission 
health facilities was carried out by the Rational Pharmaceutical Management Plus(RPM 
Plus) Program of the Management Science for Health(MSH) in collaboration with Ministry 
of Health Kenya. The methodology for this assessment was based on the Pharmaceutical 
Management for Malaria (PMM) Manual an indicator based assessment tool developed by 
the Rational Pharmaceutical Management Plus Program in collaboration with USAID. The 
PMM manual is designed to guide the review of medicines availability and the patterns of 
use of medicines for malaria treatment in public health facilities, private facilities, 
pharmacies and retail medicine outlets. This particular assessment was limited to the drug 
availability study (DAS) within the manual. Within the study, four PMM indicators 
focusing on procurement and distribution was used to asses the availability of antimaralial 
medicines within the government and mission sector of Kenya (Tetteh et al 2004). 
The study revealed that overall, in the government health facilities, antimalarial medicines 
were out of stock an average of 41 percent of the time within the specified year. The 
average percentage of the district hospital records corresponding with physical counts was 
80.36 percent, 49.06 percent for health centers and 43.44 for dispensaries (Tetteh et al 
2004). 
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The Rational Pharmaceutical Management Plus also carried out a study in Nigeria to assess 
the availability and use of antimalarials within the public and private sectors. The objective 
of the study was to identify any bottlenecks in the antimalarial pharmaceutical supply 
system and to identify appropriate points of intervention. The assessment would then 
propose interventions to address the identified problems prior to and during the 
implementation of the new policy with an aim to ensure avai lability and proper use of the 
selected artemisinin-based combination therapy (ACT) for the treatment of malaria. This 
was a rapid assessment based on the Drug Management for Malaria (DMM) Manual, an 
indicator tool also developed by the RPM project, in collaboration with USAID. The 
assessment was built around two complementary studies, a Drug Availability Study (DAS) 
and a Drug use Study (DUS). This rapid assessment highlighted some of the challenges in 
the Nigeria's pharmaceutical management system and shows that all areas of the 
pharmaceutical management cycle need to be strengthened. In summary, the key challenges 
observed by the rapid assessment included: unconsolidated procurement of medicines, 
inadequate inventory and stock management, poor record-keeping in facilities and frequent 
stock-outs of antimaralial drugs (Tetteh et al 2005). 
In addition, the Rational Pharmaceutical Management Plus (RPM Plus) Program of 
Management Sciences for Health (MSH) conducted an assessment on Health Commodity 
Management in Rwanda. The assessment addressed commodity management issues related 
to pharmacy and laboratory activities, both of which include elements of a comprehensive 
HIV / AIDS prevention and treatment program. Pharmaceutical based indicators already 
tested by WHO and RPM and other organizations were used. The data analysis was done 
according to seven main variables which included; human resource training and levels, 
availability and access to key health commodities, state infrastructure, and functionality of 
the management information system among others. The results on the drug availability 
show that among the respondents providing information on stock outs for a list of tracer 
drugs (25%), none of the referral hospitals reported having experienced stock outs of 
essential drugs during a 12 month period. Only 37% of the facilities reported having 
experienced shortages among essential drugs. No clear pattern emerged for stock-outs of 
particular drugs. However, lack of inventory control data and poor record keeping made it 
difficult to assess the true extent of stock out in these institutions (Lijdsman et aI2004). 
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Using the Drug Management for Childhood Illness (DCMI) Manual also developed by the 
RPM project, Gabra et al (2000) evaluated drug availability and use in Uganda. The DCMI 
methodology is based on 20 indicators and the reference manual includes four 
supplemental indicators that are optional. Combined, the indicators describe the degree to 
which drug availability and use affect the Integrated Management of Childhood Illness 
(IMCI) implementation in the country being studied. In the surveyed facilities, 66 percent 
of the tracer drugs were available. The inventory records of the 66 percent of the records of 
the surveyed health facilities did not correspond with physical stock (Gabra et al 2000). 
In Nigeria, according to Uzochukwu et al (2002), it was observed that the facilities which 
had received the Bamako-Initiative drug revolving fund had a better availability of 
essential drugs both in number and average stock compared to those which did not receive 
the fund. Retrospective and cross-sectional methods were used to collect data form all the 
33 primary health centers. The data collected included I isting tracer drugs in stock at the 
time of visit. (Uzochukwu et al 2002). 
Enhancing access to medicines needs concerted action and can only be tackled with the 
commitment of the actors involved. WHO has proposed a framework of complementary 
approaches for collective action. The four components of this framework are: rational 
selection, atlordable prices, sustainable financing, and reliable supply systems. Other 
strategies needed to support these components include National Drug Policies, Public-
private partnerships, strengthening of human resources and the reorientation of the research 
agenda (Wiedenmayer 2004). 
2.9 Summary 
This chapter has given a review of literature with regard to drug management at public 
health facilities. An overview of the drug management cycle has been explored. The 
essential drug concept and access to essential drugs in developing countries has also been 
documented. The literature shows that most studies in this area have used standard 
indicators to evaluate drug management. Indicators developed by WHO and RPM Plus 
have been used in several countries in Africa, Asia and Latin America. The literature 
review has mainly relied on reports and studies from international organizations and to a 
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lesser extent on peer-reviewed journals due to the limited empirical evidence available in 
this field. 
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CHAPTER 3: RESEARCH METHODOLOGY 
3.1 Introduction 
This chapter provides a conceptual framework used to analyze the drug management at the 
public health facilities. A detailed description of the methodology used to collect both 
qualitative and quantitative data, the nature and sources of the data and how such data will 
be integrated for the later stage of analysis is also presented. 
3.2 Conceptual framework 
Managing drug supply at facility level directly affects the quality of health care. If drugs 
are consistently unavailable, patients suffer and staff loose motivation. Everyone looses 
confidence in the health system, and patient attendance decreases. A constant drug supply 
promotes effective care, inspires confidence in the health facility, and contributes to job 
satisfaction and self-esteem among staff. Every health facility, however large or small, 
needs to store and manage its drug stocks. There must be systems to ensure; secure storage, 
storage in correct environmental conditions, accurate record keeping, effective reordering, 
effective stock rotation and expiry monitoring, and effective fire and theft prevention 
(MSH, 1997). 
Good inventory control makes ordering and drug management easier. Essential drug 
programs place a high priority on improving inventory control to ensure reliable supply of 
essential drugs, vaccines and other items at health facilities. Accurate and current stock 
records are essential to good inventory management. They are a source of information to 
calculate needs, and inaccurate records produce inaccurate need estimates (and problems 
with stock outs and expiry). A prerequisite for good inventory control is the training of 
staff in inventory management (MSH, 1997). 
Availability of drugs at the health facilities also depends on drug use pattern. Irrational 
prescribing habits often lead to misuse of drugs and wastage of resources. This mainly 
depends on the availability of trained medical personnel. In order to ensure rational drug 
use, continuous training and standard treatment guidelines should be put in place. The 
factors influencing drug management are closely interrelated. The Figure 2 illustrates the 
I inkage among these factors. 
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3.3 Study design 
Figure 2: Conceptual Framework 
EFFECTIVE DRUG 
MANAGEMENT 







-Monitoring and supervision 
A descriptive and analytical cross-sectional study design was used in this research. Data 
was collected at one point in time and tried to describe the situation at that particular time. 
This was preferred because it provides a rich source of information in a short period of 
time. 
3.4 Sampling strategy 
The country was stratified into rural and urban regions. Two districts, Kampala and Mbale 
(now divided into two) were purposively selected, one from each region. Compared to 
other districts, Kampala has more developed infrastructure. The NMS which is the main 
supplier of the essential drugs to public health facilities is also located near Kampala. The 
health centers are easily accessible and are run by better qualified staff It is assumed that 
availability, access and management of drugs is better in Kampala. Geographical access is 
not a major limiting factor. Kampala district has a total number of 15 public health 
facilities, which includes 4 hospitals, 2 Health Centers of level IV, 7 of level III, and 2 of 
level II. The district is divided into five administrative divisions of Nakawa, Kawempe, 
Makindye, Rubaga, and Central. 
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On the contrary, Mbale district, located in eastern Uganda, is further away from the NMS. 
Most of the health facilities are located in remote areas and are run by less qualified staff 
and are expected to experience more problems of supply and distribution of essential drugs. 
Geographical access is a limiting factor and therefore availability and access to essential 
drugs is expected to be relatively poor. Mbale district has got 6 health sub-districts and 45 
government health facilities which includes 2 hospitals,3 Health Centers of level IV, 30 of 
level III and 10 level II. 
From each district, 10 health facilities which included one hospital were selected. For 
Mbale district, the remaining 9 Health Centers were randomly selected by at least choosing 
one from each of the 6 health sub-districts. For Kampala district the remaining 9 health 
facilities were randomly selected from five divisions already mentioned. A numbered list of 
all units from which samples were to drawn (sampling frame) was made. The required 
number of sampling units was selected using a lottery method. All the units were assigned 
numbers which were mixed and the required number of health units at each level was 
drawn at random. To enable getting a representative sample from each level of care, the 
health facilities were stratified into the 4 categories of care as shown in Table 3 below. 
Table 3: Districts and Health Facilities sampled 
District Hospital HC IV 
Kampala Old Mulago Naguru 




















The higher level facilities are expected to use a wide variety of drugs. This is reflected in 
the Uganda Clinical Guidelines (Ministry of Health 2003b) and the Essential Drug List of 
Uganda (National Drug Authority 2001) both of which specify the level at which different 
drugs should be used. 
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The district hospital or He IV acts as a referral facility for a Health Sub-District (HSD). 
The district hospital caters for a population of 500000 people and He IV 100000 people. 
The leadership of the HSD is located in an existing hospital or a He IV located within the 
HSD. Its functions are primarily: 
• Provision of basic preventive, curative and rehabilitative care in the immediate 
catchments; 
• Provision of second level referral services for the HSD including life saving 
medical, surgical and obstetrical emergency care such as blood transfusion, 
caesarian section, and other medical and surgical interventions; and, 
• Provision of the physical base of the HSD Management Team. 
The He III offers continuous preventive, promotive and curative care and provides support 
supervision of the community and He II under its jurisdiction. There are provisions for 
laboratory services for diagnosis, maternity care and first referral cover for the sub-county. 
It caters for a population of 200 000 people. The He II represents the first level of interface 
between the formal health sector and the communities. The He II provides only 
ambulatory services. except in strategic locations (e.g. poor access to He III or He IV) 
where interim strategy maternity services are being provided. It caters for a population Of 
5000 people (Ministry of Health 2005b). 
3.S Types of data collected 
The data that was collected was mainly concerned with the management of essential drugs 
at the health facilities. The cross sectional data collected. the source and tools used is 
summarized in table 4. 
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Table 4: Data, Source and tools used for each objective 
Objective Information/data needed Source Tools 
I Availability of essential drugs at Records Survey forms* 
health centres Interviews Sem i-structured 
Causes of drug shortages interviews 
12 Safety, efficacy, and quality of Records Survey forms* 
I 
drugs 
·3 Stock out duration and average Records and Semi-structured 
time between re-ordering and interviews interviews and 
delivery of drugs survey forms* 
4 Presence of effective stock control Records and Survey forms* and 
system and alternative sources of interviews i semi-structured 
• drugs interviews 
i 
5 Qualification of staff in charge of Records and Sem i-structured 
warehouses interviews interviews 
*Source: Ministry of Health 2002. Adopted from WHO 2002 
The key informants interviewed included an official from the NMS, an official from the 
pharmaceutical department Ministry of Health, an inspector of drugs, two district directors 
of health services, twenty heads of the health facilities and twenty personnel in charge of 
the drug warehouses. 
3.6 Data collection methods 
Both qualitative and quantitative data was collected. Data was gathered from facility 
records, through observations and interviews with key informants at the health facilities. 
Availability of the key essential drugs and the presence of expired drugs on the shelves 
were verified by physical inspection of the drugs in the warehouses and cross-checking 
with the stock records. Outcome indicators as described in the WHO operational Package 
for Monitoring and Assessing the Pharmaceutical Situation in Countries were used. Survey 
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forms from the same package were adapted and used to assess the following indicators: 
availability of key drugs, expiry of drugs, adequacy of storage facilities, and the stock out 
duration of drugs (Brudon et al 1999). Survey form I (see appendix A) consisting a list of 
20 key drugs, was used to determine the availability and expiry of drugs for HC II and HC 
HI. For the district hospitals and HC IV, survey form 2 (see appendix B) was used. The list 
of drug requirements for HC IV and the district hospitals was modified to cater for the 
additional drug requirements at this level of care. The list of key drugs was compiled used 
the Essential Drug List of Uganda (National Drug Authority 2001) and the Uganda Clinical 
Guidelines (Ministry of Health 2003b). 
The percentage availability of the key drugs and the percentage of expired drugs at each 
health facility were calculated using the following formulas respectively: 
% of key drugs in stock No. of key drugs in stock x 100 
Total number of key drugs 
% of key drugs expired = No. of key drugs expired x 100 
Total number of key drugs 
Key informants were interviewed to find out the reasons for drug shortages and to suggest 
ways of improving drug availability (see appendix C and D). 
In order to determine whether the warehouses were suitable for storage of drugs physical 
inspection was carried using survey form 5 (see appendix E). The form consists of a 
checklist which was used to rate the condition in each of the drug stores at each public 
health facility. The ratings for all the items on the check list were summed up to obtain the 
rating for each facility. 
The stock out duration of the key drugs was determined by reviewing the stock cards for 
the six months period prior to the survey from June 1,2005 to November 31,2005. Facility 
staff was also interviewed for the same purpose. Survey form 6 (see appendix F) was used 
for HC II and III, while survey form 7 (see appendix G) was used for HC IV and district 
hospitals. The stock out duration of the drugs was calculated for each health facility 
following the procedure in the survey form 6 and 7 (see appendix F and G). 
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The proper functioning of the inventory control system was verified by cross-checking the 
accuracy of the stock records. At each health facility IS stock cards of the key drugs were 
checked and the stock levels of the drugs recorded were compared with the actual physical 
stock available in the store. Where stock records and physical counts did not correspond, 
recent issues or receipts that had not been posted were reviewed and adjusted records were 
calculated. Survey form 8 and 9 were used (see appendix H and I). The percentage of the 
records that corresponded with the physical counts was calculated using the formula: 
% of records corresponding 
with physical counts 
No. of records that correspond with physical counts x 100 
Total number of documents reviewed 
The qualifications of the personnel in charge of the drug warehouses were also verified 
through interviews and documentary evidence. The lead time and the main suppliers of 
drugs were verified through interviews and review of records which included purchase 
orders and delivery notes. 
The availability of the Essential Drug List (EDL) and the Uganda Clinical Guidelines was 
also verified through the interview with the respondents at the health facilities. Only the 
copies that were physically present and intended for use as reference for the health workers 
were counted. 
The results were compared to the international recognized performance indicators and 
performance targets as adopted from Management Science for Health (MSH). These 
indicators have been widely used for many years by MSH/RPM and other organizations 
such as WHO that have considerable expertise in drug related areas. Table 5 shows the 
details of the indicators and the performance targets. 
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T bl 5 I d" a e : n Icators an d h t e per ormance targets 
I Performance indicators Performance targets 
Health units: Indicator drugs available (unexpired) 90% 
Health units: average stock out duration for indicator drugs 10 days 
i Stock records correspond with physical counts 90% 
Average lead time from NMS to health units, routine orders 30 days 
Health units with expired items 25% 
Source: AfSH, 1997 
3.7 Data management and analysis 
Data analysis was done immediately after the completion of data collection. Both 
qualitative and quantitative analysis was carried out. Data was entered manually from the 
survey forms into master spreadsheets, checked and cleaned by a system of double entries 
into twin spreadsheets for each survey form by separate members of the research team. 
After data entry, the spreadsheets were compared and cross-checked. The standard 
Microsoft office packages (Excel and Microsoft word) were used to analyse the data. 
3.8 Ethical considerations 
• 
Before conducting the study, approval was requested from the Research and Ethics 
Committee of the University of Cape Town. On receipt of Research Ethics Committee 
approval, further authority to conduct the study and review relevant records in Uganda was 
obtained from the Ministry of Health, Uganda. Permission to review documents and extract 
data was sought from the relevant authority of the participating public health facilities. 
Semi-structured interviews were conducted with the key informants at the public health 
facilities after seeking consent thus ensuring autonomy of the persons involved in the 
study. A letter of consent (Appendix J) was read and signed by the participants as proof of 
consent to participate in the study. The participants were assured of the choice to withdraw 
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form the interview at any point in time. Since the retrieval of the information involved 
sensitive issues, participants were assured of their confidentiality. 
3.9 Quality control (validity and reliability of results) 
The interviews were conducted in English and all the survey instruments were written in 
English because all the participants had a good command of the English language owing to 
their level of education. In addition, English is the official language in Uganda. 
A pilot study was conducted prior to data collection to test the reliability and validity of the 
survey instruments. In order to ensure completeness and clarity, all interview schedules 
were saturated to my supervisor for comments and they were tested prior to their use. The 
pilot study was carried out in 4 health centers. Reliability (ability to produce consistent 
results) was determined by re-administering the survey forms to each of the pi lot premises 
using different research assistants and the results were compared. 
Validity was evaluated by checking whether pilot study participants understood the 
questions and gave appropriate answers. The interviewer recorded questions that were not 
understood, or those that required further prompting or explanation. Participants were 
invited to comment on the questionnaire. Based on the feed back received from the pilot 
study the questionnaire was modified to improve its validity and reliability. 
3.10 Summary 
This chapter has presented the conceptual framework used to analyze the drug management 
at the public health facilities. The research methodology used to conduct the study has also 
been presented in detail describing the study design, the sampling strategy, type of data 
collected, and the data collection methods. In addition, the ethical issues and the quality 
control of the results were also discussed. The data was based on qualitative and 
quantitative primary and secondary data from the public health facilities and the key 
informants. Data was analyzed using Microsoft excel and narrative qualitative analysis. 
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was 62.2% with a range of 0 % to 100%. Table 6 shows the results of health centers Hand 
III combined. 
Table 6: Stock availability on the day of survey for health centers of level II 
and III in Kampala and Mbale Districts 
. 
Drugs % of Health Centers in which the 
drug was available{n = 14} 
~l11oxicillin capsules 2S0mg 78.6 
i 2.Acetysalicylic acid(aspirin)tablets 300mg 100.0 
3.Chloroquine tablets ISOmg base 100.0 
4. Cotrimoxazole tablets 480mg S7.1 
S. Ferrous sull2hate/folic acid tablets~00mg/400mcg 92.9 
6. Mebendazole tablets 200mg 100.0 
7. Metronidazole tablets 200mg SO.O I 
8. Retinol(vitamin A) capsule 100,000 IU 8S.7 
! 9. Sulphadoxine/pyrimethamine tablets SOO/2S0mg 92.7 
10. Benzyl penicillin injection Ig(IMU) 8S.7 
I I . Methylergometrine injection 200mcg/ml S7.1 
12. Gentamicin injection 40mg/ml 3S.7 
13. Hydralazine injection 20mg/ml 0.0 
14. Magnesium sulphate injection SO% 7.1 
IS. Measles vaccine 78.6 
I 16. Medroxyprogesterone injection ISOmg/ml 78.6 
I 17. Benzoic acid + salicylic acid ointment 6%+3% 0.0 
18. Paracetamol syrup 120mg/Sml 0.0 
i 19. Oral reh~dration salts(ORS) 64.3 
I 20. Tetracycline e~e oi~tment 1% 100.0 i 
The results for the district hospital and HC IV show that paracetamol syrup, magnesium 
sulphate, were not available in any of the health centers, while hydralazine injection, 
ceftriaxone injection were only available in one health center (16.7%). Ciprofloxacin 
tablets, cotrimoxazole tablets, lidocaine HCL injection, methylergometrine injection and 
cimetidine tablets were available in less than of the health centers. The results also indicate 
that ketoconazole tablets, mebendazole tablets, quinine DI-HCL injection, clotrimazole cream and 
tetracycline eye ointment were available in 100% of the health facilities. The average was 63.3 with 
a range of 0% to 100%. Table 7 shows details of the results. 
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Table 7: Stock availability on the day of survey for HC IV and Hospitals in 
Kid Mb I d· . ampa a an ae Istncts 
Drugs % of Health Centers in which the 
drug was available(n = 6) 
I. Amoxicillin capsules 250mg 83.3 
2. Ciprofloxacin tablets 500mg 50.0 
3. Quinine sulfate tablets 300mg 50.0 
4. Cotri moxazole tablets 480mg 83.3 
5. Ketoconazole tablets 200mg 100.0 
6. Mebendazole tablets 200mg 100.0 
7. Metronidazole tablets 200mg 83.3 
8. Lidocaine HCL injection 2% 50.0 
9. Quinine DI-HCL injection 600mg/2ml 100.0 
10. Ceftriaxone injection I g 16.7 
II. Methylergometrine injection 200mcg/ml 50.0 
12. Gentamicin injection 40mg/ml 83.3 
13. Hydralazine injection 20mg/ml 16.7 
14. Magnesium sulphate injection 50% 0.0 
15. Cimetidine tablets 200mg 66.7 
16. Medroxyprogesterone injection 150mg/ml 83.3 
17. Clotrimazole cream 1% 100.0 
18. Paracetamol syrup 120mg/5ml 0.0 
19. Sodium Chloride infusion 0.9% 50.0 
20. Tetracycline eye ointment 1% 100.0 
The key informants were interviewed to find why there are drug shortages in the health 
facilities. They included heads of the health units, personnel in charge of drug stores, the 
District Director of Health Services (DDHS), regional inspector of drugs, an officer from 
NMS, and the Ministry of health. The different categories of the respondents gave different 
opinions on the causes of drug shortages. 
One of respondents from the NMS blamed the drug shortage at the health centers on the 
delays in getting orders from the districts. It was further noted that in some instances the 
NMS is unable to supply all what is requisitioned due stock outs of some drugs. This was 
attributed to the delays in the bureaucratic procurement process since more than 90% of the 
drugs used in the country are imported. A respondent from the Ministry of health was of 
the view that the drugs would be sufficient if the health centers had the capacity to make 
accurate assessment of their drug needs. The district officials interviewed shared the same 
views but he mainly blamed the shortage of drugs on insufficient funding and the delays in 
processing orders by the health units and the delays in delivery by the NMS. 
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When asked comment on the drug shortages, the inspector of drugs mainly emphasized 
lack of accountability, poor record keeping, lack of trained personnel, poor staff 
motivation, and the irrational use of drugs as the main causes of drug shortages. The 
respondents at the health centers when asked put the blame on the lack of efficiency by the 
NMS. It was reported that in most cases there are delays in delivery, partial deliveries due 
to stock out at NMS. Inadequate finance and delays in the release of funds was also cited as 
one the reasons. Box I summarizes the main reasons for the drug shortages. 
Box 1: Reasons for the drug shortages 
Delays in the requisition of drugs by the health units and delays in delivery by the 
NMS. 
2 Shortages of some of the key drugs at the National Medical Stores leading to 
incomplete deliveries. 
3 Insufficient funding and delays in the release offunds by the Ministry of Health 
4 Lack of sufficient knowledge in drug quantification which leads to inaccurate 
estimates of the drug needs by the health centers. 
5 Poor drug inventory management at the health facilities. 
6 Lack of trained personnel in drug logistic management at the health centers. 
7 Irrational use of drugs mainly due to poor prescription habits at the health facilities. 
8 Theft and leakages of drugs in the drug supply chain 
9 Poor staff motivation of staff at the health facilities 
The above reasons for the stock outs of drugs at the public health facilities previously 
mentioned were the final themes that came out after the analysis of the qualitative data. 
Some of the quotations from the key respondents supporting some of the reasons are 
presented in box 2. 
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Box 2: Direct Quotations from Key Respondents on drug shortages at health facilities 
Respondent 1 (Warehouse in-charge) 
"The drugs can never be enough. People are so many and some of the fast moving drugs 
are used up within one week of supply" 
Respondent 2 (Head of health unit) 
"Those people in the National Medical Stores are not serious. When you make an order, 
they can only manage to supply half of the items and yet we cannot be given the funds for 
items not supplied" 
Respondent 3 (Warehouse in-charge) 
"We have so many patients and the drugs are not enough. The majority of the patients are 
sent to buy drugs from the private drug shops and pharmacies for most of the drugs which 
are out of stock" 
Respondent 4 (Head of health unit) 
"The problem is National Medical stores. They take long to supply the drugs. When you 
make an order sometimes it takes more than two months to receive the drugs. Meanwhile 
we have nothing to give to the patients. We have complained and given up. Our hands are 
tied up there is nothing much we can do". 
Respondent 5 (District Director of Health Services) 
"You know very well that drugs are very expensive. They take a big share of our budget 
and we can only buy drugs which are within our budget. Our health units too have got their 
own problems. They cannot make their requisitions in time and delays the procurement 
process". 
Respondent 6 (Ministry of health official) 
"Okay, most people will say funds are not enough. But the problem is mainly lack of 
proper quantification of the drug requirements at the districts Remember that we still have 
a problem of poor drug management. One can not rule out leakages and theft of some of 
the drugs" 
Respondent 7 (NMS official) 
"I think you are aware that most of the drugs used in this country are imported and 
definitely you expect delays in the procurement process. But a part from that you that we 
are supplying drugs to all government facilities in the whole country. I know we have 
shortages of some drugs but I would like to assure that we are doing our best" . 
. Respondent 8 (Inspector of drugs) 
"The situation of drugs at these health centers would not have been all that bad. There is no 
proper accountability for these drugs. You know that the salaries of the health workers in 
these facilities are very small and they have to survive. So what do you expect?" 
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\n U~C>CSStnCnl of the' aH'ral:~ dUralion "r Ih" ~h "::" outS of Ih" inJi"iJual drugs ,hal 
occurred during till' ~ i \,. m(lll' h ~.,.'( .... \\;;L' ul",~ made. 1 h" g" l'"j ~ n ;ndkallQn (.r hu" Ion!! 
lhi.> Sloe l. OlliS la5tN. t he rt'5U hs ,hoI' I h~1 some of ' he dnl£~ I ~",I a high ", crag,· 
pcrc..,,"lng~ s./od OUI dural ion of IlK' S;'" mOlllh dllrauon. H~ Jr"d1azmc mjcclh'll'l.3Ild 
MUglll-" iulll w 1pll(tle ,njl'Ctiun lien: lOU! "fst .. ..::k ,,'( 100 lX'rl'~"1 M ,h ... ~ i \ Inun,lI p~iuJ 
su l,,;, jo.., aciJ OIn tmenl \}~.'I" ... ('cilialllicin 
iuj(,'<:IIUn 77 . 8~ ~. \ 1 ~lh>l\:rg'lnlClrin<: mj ~~II"n ,17.3-•. ll)lrimu,nhlic I~hl "l'..l~ ~ •• nnJ 
~k1((1l1 id:II;.)lc Illb k1 ~ 41 .to. Tabl~ 8 sh""s d.oUlil~ ullh~ r~>u lb "., hcoll" C<.'l1lr" II :lllJ 
III C\llllhincd. 
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1 alll,' q shim ~ lh ... 3, ,~~ [1<:n;.-nt~\..., dUrJIHIf! "I 'ltl\; ~ 01." Ilt tile dnll:' lor tk:ahh .:ellt e .... 
1\' and D"I"ictll{"'f!"at ~ lllc ~uh'i ",(!oc(lIe that \lacnt,iunl ,uJ(lhl' " 'n,.,..'t~'"' ";., \"-'1 \" 
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-.1 .-.1 .\, ..r"\!~ ,.· ... 1 lim., frul" ~II PI,II<'n I., " :" .... holl <t"" .,r 'b t It",,"b raeil i"l'~ 
I ,-.. II (,me i\ Ille 11111,' 1>0,'1'\<'>:" Ihe ,",I"ilkJn 01' 111 ... fII" ,·h .• , ... nr ... ;. ... 3n'" receipt 01',11<, gO\lO.ls 
~I (h" "Jr~ho" .... hUlIllhc .,cl,."IN ~"I'I'Ii~, Ih~ ~\<'f':J~ 1,,:lIi I ,m~ ror DII (he f:s..,li!i~ "':1) 
UI'I'I"O\ ;lIl:1 lc1 ) 2 !II"mll'o 1"0 I .... ,hll'" 11(1*.) 1\'1'1.I!1<'d ic:,,J lim" of lul l' a ",,,mh -.I 
IU~ '''II~ \~V'.I I IlluUlh , IU r,Io.II'I'~'" (~U-., 2 1""'''lh,. ~ lildl ill '-~ (I U" .. I 3 monlhs 31Jd ~ 
fa" i l ",~, (I (".14 1I1011(h, I :Ihle IU .1101', Ih,' Ic,wtmK' ,.f lI 'IT"'\~lI IWAhll lit~""k", 
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• '" • " -" 1.85 • " ,• " D 0 '" , > " < '" U,ban Ru,al 
4.:' Qll ali'~ "f tlrll ~' at Ill\' I'lIhlk ht~, II h f,.d lili.·, 
1'1..:: $IalUS ('If "">S.'1I1 ml drug <.lo mg,C' in fl'Ilblk h.::all h '-adl ,';,., \\~ J dcrrn incJ a' ~" i"di .... ...,1 
m~.'~U! c "I' II ", <lu"lil~ "I .Imp. 1,,:Io}.."I"~lc ,I< .... ~~,. urnl di"rih"I;,," "'HI kad I{> rI') ,i~al 
d ... kri\lr~li"l) and dl<'"",,~1 dl""""'f'O'-,\!,' n "'JI I(,','<I po1""K'~ . an'! l'Cca>lonall}. lom.altoll of 
lo\i~ I') -pr\oJu~ls "r deg"~al i",, \d, ... III .... '.' I'f Sl"r~;! ... 1.(1) Ix' u",,-'11 a., " rro~) mc.'l.~ure lor 
,1).: q.mli l} or drugs, I he s' ud~ r"'cabllhal Ih" '10'':!gc fae ,lil,c, had all a\ ... rag'" ~"r ... "f 
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rhe rr~ .... ncc of c\pi rcd drug~ in rhl!' sh<,he ~ " r lhe (/roC \lurM in Ihe helllih Ia.; Ilil.l'\ ".n 
~"'llhcr fllClor ,Xln , jdcrN in as'oCso;i ng rhe 41.1.11.1) OIlhe drulI' -r he re)ulh 01 till' "-ud) 
silo" Ihal4 ii.ci li,ie-; (~O",) I,crt' 1<lIloJ "nh .>ne (Or "">1'(' C~ rlf'tlJ Jnt~, un Ihl' shche'i . I he 
mc.:l.lIn pt.'lI!cnlagc ,,1 C'\p in"J Jrull~ "." flO. "h.le lhe ~\cra~1' "ih1'. 
4.6 Em_'~I'\t' iU lt'IHOI1 cUlll rol Sr'h' ''' 
I. ifL"CIil C ~ 1Vl'k cvlltr,,1 i, I pr<.'r • .",!u;",c hlf Cn~d"l' dnlg !11Magettll'nt UI Ihe I"thlic hc:.llh 
filCiH ,ies. I he f'C'1I!C1Hagc of ' I, ..... ~ (i.'Conl , Ih~1 cv,n" r>unJ "'110 the ph)'; ~;'1 ~""Ill II I dn.s, 
"3) Ihe.,1 1U mca~, re Ihc "'\l"II'" .... m:m"fel11 (.'111 ~1r.'f11\ru1C(.' All ,h ~ h':;ll! h f.'l.dh,,,.,, 
"""C)ru hitd ... ock ca.J~ ;a1.1 "cre """l! lh~n rhe ;'HW~C munbcr "I recor"~ Ii.,. ~lIlh ... 
i:)C,ltlin 11>:11 C<~'IIJt"d I"lhc l'h),,~;.I."ulI" l~ Ihe IIIIIC,,[ (he 'line) "",16·. "'I li a 
r.mb .... (If ()O . h. IIlI" •• 111.] a rnc<Io~1I \ .,luo." ,)( 16.7".. I able [ ( ..00", dCla ,l, "f I he fe,u lh" 
T9hl., I I : 1'."',' (",, Iwgt" .. r f'(oc"nh ,'u",,,,.,, ,,,,.i,,\,: ., i, II rh~ I'h~ .. k~ ' ,'"" III I" I h., 
he,lilh f:lcilli.·, ill 10.::11111':0 1:0 ,,,, ll \ lh~ I., ,li., ld ." s 
1I",.!!h r"dli' > """lh" . " r n ...:"nb "il ll~ -I . .. r n'~ .. r l[' ~ur ..... puudlllg 
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Fil!UIl' I:' ~1I "lInanl.'S Ih" p<'r liJrm:ln.::,' .'1 1I1i: ~"ilh ~~'lle" "' u:'nn, ..,1 ,.'cord, ,hal 
clIrn:'p< 'II,kJ "il ll ph>'i"", ~,'unt'. II I' c~jdi.'\1 ,hal ""JJ '~I" th.?".' t",,,hh ccm.." I",d 
mOle d'JIl 75·'. " I Ih.., "-'C' NJ~ dl~1 "'M~'I"'ndl"t "it" lit.., ph) ,k,.1 "")11 111 
Fig u rc 12: I'f'r~cnl a~f' "r r.'<.'Ord, .h~1 ,-orn"'I>I", t! " il" I'h.\ ,i<·~1 ,·011 II. fur 11.·:1111. 
r:l~ilili..,. ill ""I11I'"b !"I<I \lh"I.· ,lhlrio:l~ 
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" 25-50 ~1·7 ~ " % of lICC", .lc reCDrds 
The :lCeumc~ or .he ree"rd, " '" ~I;,(. ~(""I~d Ii ... the rUfl,1 ,qJJ urban "eullh l"<:ntl"TS The 
n,r..1 hC<lh h lac,I,.,.." "'oJ :Ill a ' ~mg~ "f n.~·" .' ...... 11-.:1' Ih~( WI re'J'ulId<"d "i." (h," ph~ sic,,1 
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In aJJ" ioo. Ihe 1e",'1 (l f lr:llnm1l (l11h.: >I.,.tI on ~hJf}:~ '" til<' JfII~ _, .. ",,_ ",", " "..1 ... , 1 J .gur.' 
I.J lIo. ..... ribl:s Ih,' dirkren, ' r.l,njn~ or lhe ", .• 11 11k' ~·",~~"n,·, i".'lu,k' "ll"e ... ttlld·""e\. 
rll!lI'TIla.} 'l"(.hnjdan~, pharrnaci<;t ~nJ "on..., m:m:lg~r, Th .... " "~r., 1111)"., pharIlL"" h. I 
(S- _I rh3ml:lo.) Il ... hnl~i:.n. 16 (H{I"., nul'loC" 11110.1 .. i\ ,.,. nn" I I~·.' ,'" ...... nM".,~.·, '\"1<'"11 
th.:m o"l~ I (~O"'. , "cr\." l.:>rmali> Iral1 ... 'tl Ill I"~"h.~ m,m~~~m,~l1 I he ""'18U".) r,'JlI"'~" 
.. df U"'J,m"lI un ,he luI> 
~ il!Y '" I .. : ( :Oil,)!' " '''''' uf ",:orf l r:u";"1; 
" .1 ,\ .. ,iI~I"II!' " f th,' t:w: ,,,i~1 !l.,.!! U , I y nd II,,· l 'I!" lIlly ( lin",,, I t •• iddin"" 
I h,' I ' .. ~nll;1I [Iru~ I 1'>1 ,,' L !I;ln":, II I II I I pn" ,110..,. J "'·1 ....... ,"''' 1.\1' dru~, 10' k' u~'" al Iht 
!'uhlt<. heul1h (:,..il IIi,.,. ,d,,1e Ihe l ,~;,,1J;o ""m al ,:'lIIktiroo: .. Il '< (. I a ""I!;n.' .... ,' ....... r.~ IIIaI 
~ul'I"""~ ""'/'\' arI'rt'f'l,al.' f'I\· .... ,I .. 'n~ I he I ,-'I.:n1l:,1 (In.I )! I 1'>1 "~I l g"",b "", ", JII~"k m 
In I ~("'"' fOr Ihe I\,,:,lth falll"" .... :111" th,- 1 !I':IIIJ~ llmll •• 1 (""",,1,,, ..... III I:: (1)(1"., <1 I'1h., 
f: ... illlk,_ I he rc,uh, ",,' I'f\· ..... "'~" III I i~un' I ~ 
I'i;:" n' 15 : "\"lIi lahili,) of,h.> .:Ut l alld the I C(: lI! Ih.· hea hh radli! i,,, ill 
" 'l tIIl':!lw lI lid i\1I",lt lli'lriel ' 
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Tuhl~ l3 br~ah dmln th~ 31:ulubdi{1 of the l ljl:andu 1- linleul GUidelines b) (.lCllitl nIX', 
I l ' l "' ufflld lil) ~ II mlwr {If f~,'i lifl.." F"dlili{',,, Ilh -.• fof l'adlUit', II lilt 
surw)('{1 l. CC; IJC(; 
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4.11 \I",,, "'1'1,li",... or dril l!' 
The I1\dm 'urrli~" 01 ~~knu.,llltug~ 10 I"" rut-lic 1 ... ",llh f: ... ,lili, ... in l g.mJlI is I"" :",'11011 •• 1 
\ 1.-d1,;;.1 'lor..'" "hId, 1~.1n aO''''"lOlI~b ... rug ""rrl~ 3~~n~~ rtoe pllblic hCdllh f:><:ih lleli 31\' 
OI1I~ :II ko,wUlo I'U.Ch., .... fn'I1\ ",I"., .... II·'·~' ,IO'I~ """tlll),: ;lnll!' :IlC IM'1 .1\.111,," .... ,1 II,,· 
':~M)"'" \I,'(/,~~I 'twe, rill: ... ,""C) 'c,uh .. r .... c~1 IIl;oI on!} l II ~ •• , f"dh l j, .... had 
rurcha-:..'(/ JOIl!> f."m 1"''' ,lie ph.on" ... ·,..:, .ltlJ ""I} 1 (1I1".) h:oJ r"t~h.~;.' ..... IlnJ~~ r"'''n ,"' .. 
Joml \lNIC,,1 \'"r..:- .... h,d, I.;. r, .. I, ~' I">lI' hll..ed org~"il;lli,,,\. I he ro:<1 "r Ihe he11l h facil ille-. 
h.oJ (ln l) rll l\:l1"...:J 1'011' ,I~ N.II,,''' .• , ,\l\.'JI~;1 1 'IOt\."- I ' .. ut~ If' ,~"" Jel"il, of Ihe 
r=ths. 
~ . 9 SU"'"' '' '1 
NMS aod JMS 
W, 
Thi~ (Chapler rrc ... ·tlh:J Ih" ",aJpr fj mJi "g~ in reJmi,," '" the "l>je"Clive, of Ihe ~IIIJl' Jh'Sul" 
f!l~" dl<: ' nl"r-. je\\, te, ~;II Ih ~1 rlrug ,how.!;", ,II II,,, publi, h":lhh (,·nl~r' un: m .. inl) .III': l<) 
pot,,>!" l1Ianagtlllenl The ,~ ... uh~ ;,1,,<, inrJ i .. ,,!~ Ihal tlll.>\l " r lh,· (foog ~ I,ln.·~ ,Jo ...... '1 !l1~"'·1 Ihc 
minonollm ,'oor.iilioll' o ( ~to ..... ~,<:. R~,ord keepi .. !; \\as gcncr"l1~ l'<"IOf "' "'0,1 " I the hcahh 
ecnlCN anJ Ihe "''l),"i') 1'1 Ihe hCllllh "nrk,·", "cle il<." fMm"ll) Irnino;J ill logbli(!o 
m~n".\,"'me"l. The a, ~.,..";;,, karl lillle "a, 1\\0 1ll<)lllh~ ,," rl lhe Ill :';u "'rrl,cr of ,h"U~' II as 
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available in any of the health centers II and III. This trend could probably be due to the non 
availability of these drugs at the NMS or probably due to the fact that the health centers did 
not consider them as a priority. In conversation with some of the health workers, it was 
revealed that paracetamol syrup was not a priority because of the high cost and that it could 
easily be substituted with tablets which are cheaper. Technically, the syrups are specifically 
fonnulated for children because of ease of administration. The non availability of such a 
drug is denying the clients access to the right dosage form of the drug. In addition, a drug 
such hydralazine injection which is a life saving drug but was not stocked at all most likely 
because of its rare use and high cost. Even if a drug is rarely used but vital to patient care, 
at least a minimum quantity should be kept in stock. 
Other drugs which include oral rehydration salts, gentamicin injection, methylergometrine 
injection, metronidazole tablets, and cotrimoxazole tablets were not available in the 
majority of the health centers in comparison to the rest most probably due to their high rate 
of utilization, purchase of insufficient quantities because of limited resources and the 
inability of the health centers to make accurate quantifications of their requirements. 
Magnesium sulphate injection though a first line drug in the treatment of eclampsia in 
pregnancy was only available in one health center. This was mainly because the staff at the 
health centers was not familiar with this drug (Interview data). 
Considering the data for HC IV and the District hospitals (see Table 7 page 39) 
paracetamol syrup and Magnesium sulphate injection were also not available in any of the 
health centers because of the reasons already mentioned. Hydralazine injection was also 
available in only one health center for similar reasons mentioned for the HC III and II. 
Other drugs with low percentage of availability include; Ciprofloxacin tablets, Quinine 
sulfate tablets, Lidocaine HCL injection and Ceftriaxone injection. These drugs have got a 
high rate of utilization and the same time costly. Because of the limited financial resources, 
the health centers may not be able to stock sufficient quantities. 
In theory, all the key essential drugs are kept in full supply to meet the needs of all clients. 
As we see from the results this is not happening in practice. Each stock out that takes place 
represents clients who will not receive the treatment that they were seeking at the health 
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care facility. The availability of the drugs on the day of the visit reflects whether the facility 
could offer a service and the related drug to the next client (or clients) who visit a health 
facility. This indicator simply provides a snapshot in time and does not represent 
continuous availability over time. Therefore the data on stock availability at the time of 
survey visit must be interpreted cautiously. 
An assessment of the average duration of stock outs provides a more in depth look at how 
long the stock outs lasted and the probability that a client who sought health care during 
this time period would not have received the drugs needed. This data differentiates between 
drugs stocked out for a short period of time versus those stocked out for a long period of 
time. 
The average stock out duration was approximately 5 months. As indicated in Figure 5, 
95% of the facilities had a stock out duration of more than 3 months. The clients could not 
therefore access the stock out drugs during that period. The details of the individual drugs 
in Table 8 for HC II and HC III indicate that Hydralazine injection and Magnesium 
sulphate injection were 100% out stock for the six month period. This is not surprising as 
these drugs performed poorly in the previous results of availability. For Hydralazine 
injection this could be attributed to its rare use and Magnesium sulphate for not being 
known as previously mentioned. The drugs Benzoic acid + salicylic acid ointment and 
Paracetamol syrup also performed poorly most likely because were not taken as a priority. 
The commonly used drugs such as Gentamicin injection, Cotrimoxazole tablets, 
Metronidazole tablets, Methylergometrine injection were also out stock for a quite big 
percentage of time for similar reasons of high utilization rates, purchase of inadequate 
quantities and inaccurate quantifications. 
Considering the results for HC IV and District hospitals (see Table 9 page 45), Magnesium 
sulphate injection, Hydralazine injection, and Paracetamol syrup, showed the same trend of 
results as for HC II and HC III. The commonly used drugs were also out stock for big 
percentage of time for similar reasons of high utilization rates, inaccurate quantification or 
limited resources. These included; Amoxicill in capsules, Ciprofloxacin tablets, 
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Ketoconazole tablets, Cimetidine tablets, Ceftriaxone injection, Clotrimazole cream and 
Sodium Chloride infusion. 
On analysis of data stratified by rural versus urban, it is noticed that the urban based 
facilities had more availability of drugs than the rural based health facilities. The stock out 
duration for the rural health facilities was also higher than that for the urban based 
facilities. However, the performance for both the rural and urban health facilities is still 
much below the required standards. The slightly better performance of the urban facilities 
may be attributed to better geographical access of the urban rural centers. Better 
infrastructure in the urban area makes it easy to access the health centers. Further more, the 
urban health centers may be under closer supervision compared to the rural health facilities. 
5.3 Average Lead time 
According to the drug logistic system in Uganda, the public health facilities are supposed 
order drugs every two months. The orders are first approved by the HSD before being sent 
to the districts for final approval. The orders are then sent to the NMS which is supposed to 
distribute to the districts every two months. The districts are then responsible for delivering 
the appropriate commodities to each of the health sub-districts. Each faci I ity then collects 
their commodities from the health sub-districts (Ministry of Health 2003c). 
Timely distribution of the correct quantities of dugs is critical for ensuring a continuous 
supply. The results in Table 10 indicate an average lead time of approximately 2 months 
with 20% of the facilities having a lead time of more than 2 months. According to MSH 
(1997), most public programmes use an interval of one to three months. The average lead 
time of approximately 2 months is within the acceptable limits provided that the supplied 
drugs last up to the next delivery. The rampant stock outs as already observed could be 
partly due to the supply of insufficient drugs which cannot last up to the next delivery 
cycle. There should be safety stock (butTer or minimum stock) kept on hand to avoid stock 
outs. The stock outs can occur because of delays in delivery or if there is unexpected 
increase in demand. 
The delayed deliveries observed for some health centers, could be attributed to delays in 
the processing of the orders by the NMS and late deliveries to the districts. In the same 
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way, the districts may delay the deliveries to the individual health centers. The NMS is 
supposed to deliver products to all the districts of Uganda. This is an enormous task which 
requires a high level of organization and an efficient transport system. The inefficiencies in 
the distribution and transportation cannot be ruled out. Poor infrastructure and road 
conditions and shortages in funding for fuel or other means of transportation often make 
transportation difficult. The NMS has no regional warehouses and all the commodities have 
to originate from the central stores making the distribution more inefficient. The average 
lead time of the rural health centers was slightly more compared to the urban centers most 
likely because of the longer distance from the NMS and the poor road infrastructure which 
is characteristic of rural areas in developing countries. 
5.4 Causes of drugs shortages as spelt out in the qualitative data 
The qualitative data from the key respondents may be used to explain some of the causes of 
stock outs of drugs at the health facilities. Among the reasons cited were the poor drug 
funding. Drug financing is linked to availability of drugs and availability of drugs depends 
among many factors on sufficient funding sources and is a key indicator towards 
determining access to drugs by the population. There five major sources of drug financing 
within the Uganda health sector that contribute to the total funding pool for drugs. These 
include: Uganda government, donors, employers, non-governmental organizations and 
households (Ministry of Health 2002d). The total drug financial resource estimate 
increased from 125 billion Uganda shillings (2001/02) to 210 billion Uganda shillings 
(2003/04) excluding funds from Global Fund, registering an increase of 23 percent per 
annum over the three year period (Ministry of Health 2004b). According to the Annual 
Health Sector Performance of the Ministry of Health (2003), the per capita funding of 
drugs for the National Minimum Health Care Package (NMHCP) increased from US$0.86 
in the financial year 200 I /02 to US$I.2 in financial year 2002/03 but there continued to be 
a large gap compared with the projected requirements of US$ 3.5 (excluding ARVs and 
pentavalent vaccine). For the financial year 2005/06 the estimated per capita medicine 
inputs are projected to be over US$4 because of the commitments for a new first line 
treatment of malaria with artemisinin based combination therapy (ACT) to be funded 
through the Global Fund for AIDS, TB and Malaria (GFA TM). This amounts to an 
additional US$1 per capita annually, which is larger than the entire monetary medicines 
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budget for service providers (Ministry of Health 2004). This shows that the funding gap 
continues to increase with the introduction of the new and expensive medicines. The 
current level of funding is not able to meet the target set out in the National Minimum 
Health Care Package. Inadequate drug financing therefore remains a major hindrance to 
providing sufficient drugs to the public sector. Therefore the problem of drug financing as 
pointed out by the respondents is not a surprise but it is consistent with what has already 
been established by the Ministry of Health. Given this large financing gap there is need to 
devise ways of improving the available financing and also determine the most effective 
ways of financing the package. 
Drug financing is inevitably linked to drug supply systems and therefore improvements in 
terms of efficiency of the delivery systems can make a significant impact on the utilization 
of the resources available. The stock outs were also attributed to the inefficiencies of the 
health units in the requisition of drugs by the health centers and the inefficiencies of the 
NMS in the procurement and distribution of drugs (interview data). 
According to the Annual Health Sector Performance of the Ministry of Health (2005a), 
routine monitoring highlighted irregular drug procurement and below target expenditure on 
drugs compared to the indicative cash budget. Contrary to the Primary Health Care 
Conditional Grant (PHC-CG) guidelines, medicines expenditure falls far below 50%. 
Funds through credit line have shown better efficient utilization than those through 
recurrent transfers with average 90% utilization. Under spending may be related to re-
allocation of funds, irregular ordering, and lor sub-optimal service at NMS. The Technical 
Review report also reveals that NMS sales have stagnated because it is unable to procure 
sufficient stocks and that performance is hindered by constraints, including lack of 
financial capital, changing regulations for procurement and longer lead times under the 
Public Procurement and Disposal of Assets Act (PPDA), and limited planning and 
management capacity. Service level (% of order of value actually supplied) deteriorated to 
50% by June 2005, compared with performance in the range of 66-75% during the period 
July 2003 to December 2004 (Ministry of Health 2005a). Therefore the low availability and 
long periods of stock outs should not be a surprise given this scenario. 
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The above scenario clearly indicates that even the little available resources were not fully 
utilized. Full and efficient utilization of the available funds would definitely improve the 
availability of the drugs at health centers. The unutilized funds of the credit line which get 
tied up with the NMS plus the under utilized funds of PHC Conditional Grants would make 
definitely make a difference if they were fully utilized. Increasing drug financing without 
improving the efficiency of the drug supply system cannot improve the availability of drugs 
at the health centers. 
According to Bennet et al (1997), the failure of government supply systems to provide 
adequate and efficient services is often seen to be symptomatic of fundamental problems in 
the public sector including: 
• Public sector rigidities, particularly bureaucratic statT regulations 
• Lack of incentives for efficient behavior 
• Pol itical interference 
• Lack of management autonomy, responsibility and accountability 
• Absence of competition and 
• Inadequate financial resources 
Drug supply systems need to achieve three main objectives which include: a high level of 
service, as measured by low rates of shortages and stock outs; efficiency, as measured by 
having low total costs for a given level of service and quality in terms of delivering drugs 
of satisfactory qual ity (Bennet et al 1997). I n recent years, a variety 0 f attempts have been 
made to introduce private sector management methods and elements of competition into 
public sector services in developed as well as developing countries (Bennet et al 1994, 
Bennet 1991). These attem pts were based on the bel ief that the key issue was not publ ic 
ownership, but rather the nature of management and the market environment within which 
the organization operates. In Uganda, the debate is still going on whether the NMS should 
be privatized or not. 
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5.5 Quality of drugs at the public health facilities 
All health commodities require specific procedures and conditions for safe storage that 
protect their integrity and effectiveness, maximize their shelf life, and make them readily 
available for distribution. When all levels of the system follow the same standards of 
storage, clients can be assured that they will receive a high-quality product. Because 
commodities are stored and transported from one level of system to another, all levels of 
storage within the logistics system must comply with a set of minimum standards to protect 
the commodities until they are distributed to a client at a service delivery point (MSH 1997, 
Ministry of Health 2003c) 
All the pharmaceuticals marketed in Uganda must be registered with the National Drug 
Authority (NDA). The drugs must be from pharmaceutical plants which have been 
inspected and approved by the National Drug Authority. The NDA is also required by law 
to inspect all the pharmaceutical products imported in the country. Physical inspection of 
all medicines is carried out at the port of entry and samples are selected from each batch 
and tested if a problem is identified during physical inspection. With all the quality 
assurance procedures followed as mentioned, it is expected that all drugs imported in the 
country should meet the minimum required standards (Ministry of Health 2002b). 
However, as already mentioned, the quality of the drugs cannot be maintained unless they 
are properly stored. 
As indicated in Figure 8 (page47) only 10% of the health centers had adequate storage 
facilities. This should be a cause of concern because the quality of drugs in the majority of 
health centers may not be guaranteed because of the inadequate storage conditions. 
According to MSH (1997), a drug product must retain its properties within specified limits 
in order to be useful. The stability of a drug product depends on the active ingredient, 
which can be affected by its formulation and packaging. Inadequate storage and 
distribution can lead to physical deterioration and chemical decomposition, reduced 
potency, and, occasionally, formation of toxic by-products of degradation. This is more 
likely to occur under tropical conditions of high ambient temperature and humidity (MSH 
1997). The unsuitable storage conditions leads to premature expiry of drugs rendering them 
unsuitable for clinical use. 
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The comparison of the rural and urban based storage facilities as indicated in Figure 9 
(page 47) shows that the average ratings for both are below the acceptable standards. The 
inadequate storage conditions as indicated in Figure 10 (page 48) were mainly attributed to 
poor design of the stores leading to high temperatures, poor ventilation, direct sunlight and 
poor drainage systems. Storage should be located in a dry weather proof building. Stocks 
should be organized and easily accessible on adequate good shelving. Space and cold chain 
equipment should be provided for the refrigeration of vaccines and other items. Because of 
inadequate shelving and lack of pallets drugs meant that drugs would be placed on the floor 
where they are not protected from humidity. Only 10% the facilities had cold storage 
facilities and only 15% had drugs protected from humidity and water. In addition a poor 
level of cleanliness, tidiness of stocks and storage rooms which is associated with presence 
of insects and rodents was also observed in the majority of the stores. The insects and 
rodents destroy the stores and the stocks as well. Figure I I (page49) shows that only 5% 
of the facilities complied with more than 75% of the storage conditions. There is an urgent 
need to improve the physical storage capacity at the health facility level. 
The presence of expired drugs on the shelves was also used as a proxy measure for the 
quality of drug at the health centers. Expired products can no longer be offered to clients. 
But when they found on the shelves mixed with the non-expired ones, there are high 
chances of being dispensed. The use of poor quality products may have undesirable clinical 
and economic effects, as well as affect the credibility of the health delivery system. Clinical 
effects can include prolonged illness or death or inducement of toxic or adverse reactions. 
On the economic side, limited financial resources may be wasted. The average percentage 
of expired drugs was 2% and they were only found in only 4% of the facilities. When the 
drugs expire, they should be immediately removed and securely stored in a separate area. 
Presence of expired drugs on the shelves is also a sign of poor stores management. The low 
product loss due to expiration was low most likely because of the short supply of drugs 
which were consumed before expiration. 
Drugs usually expire because they have been over ordered, or if the FEFO (first to expire, 
first out) has not been observed. In well run stores where orders are placed regularly and 
stock is rotated this should not happen. Most health care systems in developing countries 
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operate with limited funding; health commodities are precious and rarely in full supply. 
Therefore, losses of otherwise usable commodities due to expiration should be avoided at 
all costs. 
Reviewing the quantities of expired stock provides another measure of overall logistic 
system performance, though it will not highlight the causes or the components for any 
deficiencies in any logistic system. Some amount of commodity loss due to expiration is 
expected in any logistic system, but large quantities should be investigated (Ministry of 
Health 2003c). 
5.6 Inventory control system 
The primary purpose of a store is to receive, hold, and distribute stock. This process is 
controlled by an inventory control system, which may be manual or computer based. The 
primary purpose of inventory control is to manage procurement and stock movements. The 
system should also be designed to provide information for performance monitoring. 
The survey on a positive note revealed all the facilities were using stock cards. The survey 
collected data regarding the accuracy of the logistics at the facility level. The average 
number of records that corresponded with physical count as indicated in Table II (page 50) 
was 36% and only 6.7% of the facilities had more than 75% of the records corresponding 
with the physical count (see Figure 12 page 51). The rural-urban comparison of the 
accuracy of the stock records shows poor a performance far much below standard for both 
although the urban health facilities scored higher. Low percentages of correspondence 
between stock records and physical counts may be caused by wastage or pilferage and 
highlights problems of accountability, all of which contribute to financial losses. This poor 
performance in record keeping and lack of proper accountability was not a surprise because 
it had been earlier pointed out by the key respondents during the interviews as one of the 
major causes of drug shortages at the health facilities. 
The pilferage of the drugs is possible in developing countries where health workers are 
poorly paid and they resort to using the public resources as a survival mechanism. 
According to Birungi (' 994) the public health workers in Uganda tried to survive within 
and/or outside the system by creating institutional linkages between public and private 
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settings and many kept their jobs for reasons of access to public resources to use in the 
private sector (Birungi 1994). The NMS supplies drugs to the public sector as well as the 
private sector. The drugs supplied to the public sector are not specifically marked to 
differentiate them from those supplied to the private sector. This makes the pilferage and 
theft of drugs from the health centers easier as they can be easily sold in the private clinics, 
pharmacies and drug shops without being noticed. 
The poor record keeping observed was also mainly attributed to inadequate training of the 
staff in the drug logistic management. The survey revealed that the majority of the staff 
(80%) was in the category of nurse/midwife and this was as expected for the lower levels 
of health care. The poor record keeping was not a surprise because it is consistent with the 
poor training as revealed in the study results indicating that only 20% of the staff was 
formally trained in logistic management. Another major concern expressed by the 
participants, was shortage of staff and consequent overload of staff with clinical work and 
little dedication to record keeping. 
The personnel responsible for managing health commodities need to be trained in how to 
maintain stock cards, how to calculate order quantities and place orders, and how to fill out 
records and reports. These activities, when performed accurately, help to ensure proper 
stock management and to give an accurate picture of consumption rates and stock on hand 
at each facility. Without well-trained staff, facilities run the risk of poor record keeping and 
inaccurate ordering, which in turn can lead to stock outs, overstocks, and expired products. 
The lack of training in drug logistic management and the inadequate knowledge in drug 
quantification were pointed out by the key informants in interviews and are consistent with 
what found out during the survey. 
5.7 Availability of the Essential Drug List of Uganda (EDLU) and the Uganda Clinical 
Guidelines (UCG) 
The national essential drug list and the national standard treatment guidelines should be 
available at all the health facilities. The essential drug list assists in the selection of a 
limited number of drugs to be used at each health facility. The standard treatment 
guidelines are used to indicate systematically developed statements to help practitioners or 
prescribers make decisions about appropriate treatments for specific clinical conditions. 
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Together with the national list of essential drugs, treatment guidelines are powerful tools to 
promote the rational use of drugs. They offer an opportunity to ensure that the training of 
health workers is based on logical approach to treatment and on a consensus about the 
selection of essential drugs (MSH 1997). 
The availability of the EDLU and the UCG at the health facilities was surprisingly found to 
be low. The availability of the EDLU and UCG depends whether the Ministry of Health 
has enough resources to print adequate copies for distribution to all health facilities and on 
the ability of the staff to maintain them at the health facilities. The availability of these 
guidelines is used to measure the level of access of information necessary for effective drug 
management. There is need for the government to effectively distribute EDLU and the 
UCG to all government health facilities. 
5.8 Main suppliers of drugs 
Procurement of medicines is a specialized area that requires technical specifications to be 
met in addition to value for money considerations. For these reasons, the Ministry of 
Health guidelines require that government institutions first source their requirements from 
the NMS, use JMS as second option ifNMS cannot supply, and buy from the private sector 
only as a last resort (Ministry of Health 2004). 
The results as indicated in Figure 16 (page 55) revealed that 25% of the facilities had 
purchased drugs from other sources in addition to NMS. There was generally high 
compliance with the guidelines but this was at the disadvantage of the clients because the 
NMS was unable to supply all the drugs because of the rampant stock outs. The majority of 
the health facilities were not able to buy from other sources most likely because of the 
reluctance of NMS in giving certificates of non-availability. The funds for the unavailable 
drugs remain tied up at NMS and the patients are denied access to essential drugs. More 
flexibility should be allowed so that the health centers can purchase from other sources if 
the drugs are not available at NMS but at the same time there has to be close monitoring to 
ensure that only good quality drugs are purchased at the appropriate prices thus guarantying 
value for money. 
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5.9 Limitations of the study 
Due to limited resources and time, the study included only 20 health facilities from two 
regions. Uganda has four regions with a lot of diversity in terms of social, political and 
economic development. Therefore, the findings from this study may not necessarily be 
generalizable for the whole country. In addition, the rampant poor record keeping 
experienced in almost all the health facilities surveyed made it difficult to collect very 
accurate data and this might have introduced unnecessary errors. 
In order to put pharmaceutical indicators in context, additional information about the local 
situation may be required. The indicators cannot stand alone; they have to be used in 
conjunction with other social and health indicators. However, indicator based studies are 
cost-effective tools that measure complex systems in relatively short time and give 
investigators a snapshot to overall trends in the sector. 
However, despite these limitations, the study offers significant insights into the weaknesses 
of drug management in the public sector in Uganda. In this regard therefore, the study is of 
importance to policy makers. 
68 
CHAPTER 6: CONCLUSION AND POLICY RECOlVIMENDATIONS 
6.1 Introduction 
The study gave an overview of drug management at public health facilities in Uganda. The 
study highlights some challenges in the pharmaceutical management system in Uganda and 
shows need for improvement in all areas of the pharmaceutical management cycle. This 
section presents the main conclusions of the study based on the study objectives. The 
section also points out a number of policy recommendations to improve the drug 
management in the public sector in Uganda. This addresses the last study objective. 
6.2 Main study conclusions 
The study revealed that the availability of essential drugs in the public sector is inconsistent 
and insufficient. There was also a high stock out duration of the drugs. This has got a 
negative implication on the health care delivery in the public sector as it this leads to 
inadequate access to essential drugs by the majority of the poor who mainly use the public 
sector health care facilities. 
The majority of the storage facilities at the health facilities do not meet the minimum 
requirements for the storage of drugs. The quality of drugs stored in such facilities is not 
guaranteed as they are likely to expire prematurely. Such drugs are not fit for clinical use 
because they can do more harm than good to the patients. The presence of expired drugs in 
the stores was minimal because of the short supply and high utilization rates. 
The study further reveals that the rampant stock out of drugs at the health facilities was 
mainly due to inadequate funding by the government. However, the limited resources that 
are available are not fully utilized because of the inefficiencies by the NMS the main 
supplier of drugs to the public sector and the poor planning at the health facility and district 
level. 
Health commodity security is additionally threatened by inadequate record keeping and 
information systems. Substantial errors and omissions exist in recording stock data making 
it difficult to get accurate information which is necessary for making informed decisions. 
Regular reporting of this information is critical for making logistics decisions at each level 
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of the supply chain. Access to this data at all levels of the logistics system will increase 
product availability by improving the system's efficiency. 
Additionally, the poor drug management is attributed to inadequate human resources for 
health. The study highlighted the lack of training and inadequate ski lis in commodity 
management among the staff. Lack of capacity to adequately quantify drug requirements 
and to manage their inventory was reported as one of the major causes drug shortages at the 
health facilities. 
The NMS through its mandate is responsible for ensuring continuous distribution of 
pharmaceutical products in a financially and viable manner. Being an autonomous 
centralized drug supplier it enjoys government support. With a big financial base, it should 
be able to offer widest range of essential and vital drugs at one shopping centre. With bulk 
procurements it should be able to negotiate high discounts so as to offer affordable prices to 
the end-user. In addition the bulk operations ensure serving the remote areas markets with 
limited commercial appeal cost-effectively). However, the NMS has not exploited these 
advantages to operate efficiently. The rampant shortages of drugs in the public sector 
facilities has been mainly attributed to the rampant stock out at NMS, delays in processing 
customer orders and an inefficient distribution system. 
6.3 Policy Recommendations 
Based on the study findings, recommendations on ways of improving drug management at 
the public health facilities are developed. The study has revealed a number of issues 
regarding the drug management in the publ ic health sector. The weaknesses observed 
should be addressed in order to improve drug management which will also translate into 
better availability and access to essential dugs by the majority of the population. The 
following below are suggestions for policy consideration. 
I. There is need for the government to commit more funds in order to meet the drug 
requirements within the National Minimum Health Care Package. Concrete 
measures should be put in place to ensure that the available resources are fully 
utilized in the most efficient manner to provide the key essential drugs in public 
sector. 
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2. (n addition there is need to improve the storage conditions of the drug stores at the 
public health facilities so as to meet the minimum requirements for the storage of 
drugs. This is necessary for avoiding the deterioration of the drugs so that the 
quality of drugs is maintained up to the use. 
3. Further more there is need to improve inventory management by closer monitoring 
from the district and at national level. The National Drug Authority through its 
mandate should carry out regular inspections of the public health facilities and put 
more emphasis on proper record keeping and accountability. More training of staff 
in record keeping and drug quantification is necessary if accurate data is to be 
generated. (f possible, computerized inventory control systems should be gradually 
introduced at the high levels of the health care systems. 
4. Also measures to reduce illegal practices at the distribution stage should be put in 
place. These include improvements in record keeping and control procedures and 
fortifying against any drug pilferages at any at any stage in the drug distribution 
channel. The introduction of special packaging to facilitate easy identification for 
all the drugs intended for use in the public sector can also minimize leakages of 
drugs from the public health facilities. Transparency and accountability should be 
promoted. 
5. There is need to determine what systems offer the best incentives for providers to 
behave honestly and control fraud. There is need to improve staff motivation. Both 
financial and material incentives provided for health workers by government are 
woefully inadequate to boost the morale of the perpetually overworked health staff. 
Further more, staff specifically trained in drug logistic management should be 
gradually recruited to be in charge of the drug stores. Preferably at lower levers of 
health care, pharmacy technicians with additional training in drug management 
should be recruited and at hospital level, pharmacists should be employed. 
6. The efficiency of the NMS can be improved by contracting out of some the 
activities. Transportation and distribution of drugs could be contracted out to the 
private sector so that the NMS concentrates on the procurement as its core activity. 
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Regional warehouses should be established so as to reduce the lead times and to cut 
the transport costs. In addition, the NMS should be swifter in issuing certificates of 
non-availability to clients for the products which are not available. 
7. Alternatively the government should look into the possibility of breaking NMS 
monopoly. This can be done by giving liberty to the districts to choose between 
NMS and JMS as the main supplier of drugs. According to the Ministry of Health 
Annual Health Sector Performance Report (2005a) JMS has proved to be very 
efficient in supplying drugs to Private Not for Profit (PNFP) health units and has for 
many years been a supplier to government health facilities in the area of medical 
equipment and instruments. Additionally, JMS has been impressive in managing 
change, and sustaining growth of a well diversified customer base fully using its 
own resources, and the flexibility in financial and procurement procedures of PNFP 
institution (Ministry of Health 2005a). Breaking the monopoly of the NMS could 
perhaps create competition and improve its efficiency. 
6.4 Agenda for future research 
The study identified some information gaps that would be of interest for further research 
and guiding future policies. Future research into the role and performance of the private 
sector should be carried out to get an overall picture of the situation in the pharmaceutical 
sector. 
There is need to assess the level of utilization of the drugs at health center level in relation 
with what is supplied from the central level. This can give a clear picture of the value of 
drugs that are actually used in relation to what is supplied from the central level. In 
addition, this can give an indication of what is lost in the drug distribution chain. 
Future research into the possibi lity of control! ing drug prices especially in the private sector 
is very crucial where the cost of drugs serves as a barrier to access and to rational drug use. 
There is need to investigate hidden costs of drugs in the supply chain and determine at 
which points to intervene and reduce the costs of drugs to the patients. 
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There is need to explore other approaches for organizing drug supply for government 
health services. The possibility of full privatization of NMS should be explored especially 
the impact on availability and access to drugs by the poor. 
Further more, exploration of the role of health insurance in improving access to drugs 
including provider payment mechanisms would enable investigation of possible ways of 
pooling resources and sharing costs over different population groups. 
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APPENDIX A: A V AILABILITY OF DRUGS AT HEALTH CENTRES II AND III 
(INDICATOR: % OF EXPIRED DRUGS, AVAILABILTY OF KEY DRUGS) 
Survey Form No. I 
FACILITY 
LOCATION 
____________________ DATE ________________ __ 
__________________ ~RESEARCHER ____________ __ 
Key drugs in stock to treat common conditions[A] In stock[B] I Drugs in stock that have 
Yes=I,No=O i expired[C] Yes= I ,No=O 
I. Amoxicillin capsules 2S0mg 
i 2.Acetysalicylic acid(aspirin)tablets 300mg 
3.Chloroquine tablets ISOmg base 
4. Cotrimoxazole tablets 480mg 
S. Ferrous sulphate/folic acid tablets 200mgl400mcg 
6. Mebendazole tablets 200mg 
7. Metronidazole tablets 200mg 
I 8. Retinol(vitamin A) capsule 100,000 IU 
9. Sulphadoxine/pyrimethamine tablets SOO/2S0mg 
10. Benzyl penicillin injection 19(IMU) 
II. Methylergometrine injection 200mcg/ml 
12. Gentamicin injection 40mglml 
13. Hydralazine injection 20mglml 
14. Magnesium sulphate injection SO% 
IS. Measles vaccine i 
16. Medroxyprogesterone injection ISOmg/ml 
17. Benzoic acid + salicylic acid ointment 6%+3% 
18. Paracetamol syrup 120mg/Sml 
19. Oral rehydration salts(ORS) 
20. Tetracycline eye ointment 1% 
Total no. of drugs in [DJ [G]= [H]= 
%key drugs in stock[E]= 
% of drugs expired[F]= 
Notes: 
[A] List of 20 key drugs previously identified at a national level must be printed before 





Mark I ifstock is available (even ifonly one dosage form is available). Mark 0 if the 
drug is not physically available. Add the total at the bottom [G] 
% of key drugs in stock No. of key drugs in stock [GJ x 100 
Total number of key drugs [D] 
For all drugs in stock, check if expired or not. If any of the strengths hac; an expiry 
problem, the answer for the drug should be yes. Add all these answers = [H] 
% 'of expired drugs = Total no. of yes answers[Hl x 100 









APPENDIX B: A V AILABILITY OF DRUGS AT HEALTH CENTRE IV AND 
DISTICT HOSPITALS 
(INDICATOR: % OF EXPIRED DRUGS, AVAILABIL TY OF KEY DRUGS) 
Survey Form No.2 
FACILITY 
LOCATION 
______________________ DATE __________________ _ 
____________________ RESEARCHER~ __________ __ 
Key drugs in stock to treat common conditions[A] In stock[B] Drugs in stock that have 
Yes=I,No=O expired[C] Yes=I,No=O 
I. Amoxicillin capsules 2S0mg 
2. Ciprofloxacin tablets SOOmg 
3. Quinine sui fate tablets 300mg 
4. Cotrimoxazole tablets 4S0mg 
S. Ketoconazole tablets 200mg 
6. Mebendazole tablets 200mg 
7. Metronidazole tablets 200mg 
S. Lidocaine HCL injection 2% 
9. Quinine DI-HCL injection 600mg/2ml 
10. Ceftriaxone injection I g 
II. Methylergometrine injection 200mcg/ml 
12. Gentamicin injection 40mg/ml 
13. Hydralazine injection 20mglml 
14. Magnesium sulphate injection SO% 
IS. Cimetidine tablets 200mg 
16. Medroxyprogesterone injection ISOmg/ml 
17. Clotrimazole cream 1 % 
IS. Paracetamol syrup 120mg/Sml 
19. Sodium Chloride infusion 0.9% 
20. Tetracycline eye ointment 1% 
Total no. of drugs in [D]= [G]= [H]= 
%key drugs in stock[E]= 
% of drugs expired[F]= 
Notes: 
[A] List of 20 key drugs previously identified at a national level must be printed before 





Mark I if stock is available (even if only one dosage form is available). Mark 0 if the 
drug is not physically available. Add the total at the bottom [G] 
% of key drugs in stock = No. of key drugs in stock rGJ x 100 
Total number of key drugs [D] 
For all drugs in stock, check if expired or not. If any of the strengths has an expiry 
problem, the answer for the drug should be yes. Add all these answers = [H] 
%'ofexpired drugs = Total no. of yes answers[HJ x 100 
Total no. of key drugs [D] 
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APPENDIX C: INTERVIEW GUIDE FOR HEALTH FACILITY OFFICIALS 
Survey form no. 3 
~ it ...... ,.,... 'I. 
,.: ....... --•................... 
Name of interviewee: Position: Profession: Other qualifications: 
I. Do you have a copy of the Essential Drug List Uganda and the Uganda Clinical 
Guidelines?(Only the copies seen are counted) 
2. Do you always experience shortages of essential drugs at this health facility? 
3. (If YES to I above), in your opinion, what are the major causes of these shortages? 
4. Are their specific drugs that are frequently out of stock? 
5. Do you receive your drug supplies from the NMS in time? What are other 
suppliers apart from the NMS? 
6. What is the approximate time of delivery of drugs after making a requisition from 
the NMS? 
7. How do rate the performance ofNMS in the purchase and distribution of essential 
drugs to health facilities? 
8. Are there any other problems related to drug management at the health facility? 
9. In your opinion, what can be done to improve the availability of drugs at the health 
centers? 
10. Can you suggest ways of improving drug management at this facil ity? 




APPENDIX D: KEY INFORMANT INTERVIEW GUIDE 
Survey form no. 4 
Name of interviewee: Position: Profession: Other qualifications: 
1. The NMS is the main supplier of drugs to public health faci ities in Uganda. What 
have been the major challenges in the procurement and distribution of drugs in the 
country? 
2. Frequent stocks out of drugs at the NMS and the health facilities have been 
reported. Can you explain the causes? 
3. Delays in delays in the drugs to health tac:llities have been reported. If true what 
are the causes? 
4. W hat is being done to improve the drug management at the public health 
facilities? 
5. Can you suggest ways of improving availability of essential drugs at the health 
facilities? 
6. Can you suggest ways of improving the efficiency ofNMS ? 
Thank you for your time 
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APPENDIX E: STORAGE CHECKLIST 
APLICABLE TO ALL WAREHOUSES AND PHARMACIES 
(INDICATOR: ADQUATE STORA GE) 
Survey Form No.5 
FACILITY ____________________ DATE 
LOCATION ____________________ RESEARCHER ____________ __ 
Checklist 
to rage an s eves area are c ean no ust or Itter 
No evidence of pests seen in the area 
i There is a ceiling I 
! There is proper ventilation 
No direct sunlight should enterthe area 
There is a stock record si:stem 
Area free from moisture(leaking drains and taps) Drugs 
! 
should not be stored directly on the floor 
Drugs sorted in a systematic way(alphabetical, first expiry- I 
. first out 
i There is a separate storage and dispensing area for issuing 
drugs 
I 
! There is cold storage with a temperature chart 
Rating for the facility :{ [AJ + [B]}/2. If only one exists just • [AJ [BJ 
use rA] or rB] Ratin~ i 
SCORES 
Facility stora~e Ratin~(check) Equivalent ratin~ for quality of drugs 
• Poor 0-3 D Quality may be poor 
• Not adequate 4-5 D Quality may be doubtful 
• Moderately ad~ 6-7 D Acceptable quality 
• Adequate 8-10 D Acceptable quality 
• More than adequate 11 D Good qual ity 
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APPENDIX F: STOCK OUT DURATION I 
APPLICABLE TO HEALTH CENTRE II AND HEALTH CENTRE III 
FACILITY 
LOCATION 
(INDICATOR: STOCK OUT DURA TlON) 
Survey Form No.6 
______________________ DATE __________________ _ 
____________________ RESEARCHER ____________ __ 
Key drugs in stock to treat common conditions[ A] I No. of days No. of days Equiv. No. I 
out of covered by of days/year I 
stock(B] review[C] [D]=[B]x 
36S/[C] 
I. Amoxicillin capsules 2S0mg 
i 2.Acetysalicylic acid(aspirin)tablets 300mg I 
! 3.Chloroquine tablets ISOmg base ! 
4. Cotrimoxazole tablets 480mg 
S. Ferrous sulphate/folic acid tablets 200mgl400mcg 
6. Mebendazole tablets 200mg 
7. Metronidazole tablets 200mg 
8. Retinol(vitamin A) capsule 100,000 IU 
. 9. Sulphadoxine/pyrimethamine tablets 50012S0mg 
10. Benzyl penicillin injection I g( I MU) 
II. Methylergometrine injection 200mcglml 
12. Gentamicin injection 40mg/ml 
13. Hydralazine injection 20mg/ml 
14. Magnesium sulphate injection SO% 
IS. Measles vaccine 
I 16. Medroxyprogesterone injection ISOmg/ml 
17. Benzoic acid + salicylic acid ointment 6%+3% 
18. Paracetamol syrup 120mglSmi I 
19. Oral rehydration salts(ORS) 
20. Tetracycline eye ointment 1% ! 
[E]= Total No. of key drugs = (sum of A) = __ [F] = sum of ! 
[G]= Ave. no. of stock out days = [F]/[E] = 0= 
Notes: 
[B] Go through the card covering the review period. Add the number of days that each of the key 
essential drugs are not available. A drug is considered in stock if it is or its equivalent is available 
i in either generic or branded form. Indicate [B] the total number of days out of stock. 
I The review should a 6-12 months period. I f this is not possible then indicate the number of days 
covered by the review. 
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APPENDIX G: STOCK OUT DURATION II 
APPLICABLE TO HEALTH CENTRE IV AND DISTRICT HOSPITALS 
(INDICATOR: STOCK OUT DURA TION) 
Survey Form No.7 
FACILITY 
LOCATION 
____________________ ~DATE __________________ _ 
____________________ RESEARCHER ____________ __ 
Key drugs in stock to treat common conditions[A] No. of days No. of days Equiv. No. 
out of covered by of days/year 
stock[B] review[C] [D]=[B]x 
365/[C] 
I. Amoxicillin capsules 250mg 
2. Ciprofloxacin tablets 500mg 
i 3. Quinine sulfate tablets 300mg 
• 4. Cotrimoxazole tablets 480mg 
5. Ketoconazole tablets 200mg 
6. Mebendazole tablets 200mg 
7. Metronidazole tablets 200mg 
8. Lidocaine HCL injection 2% 
• 9. Quinine D1-HCL injection 600mg/2ml 
10. Ceftriaxone injection I g 
II. Methylergometrine injection 200mcglml 
12. Gentamicin injection 40mg/ml 
13. Hydralazine injection 20mglml 
14. Magnesium sulphate iniection 50% 
15. Cimetidine tablets 200mg 
16. Medroxyprogesterone injection 150mg/ml 
17. Clotrimazole cream 1% 
18. Paracetamol syrup 120mg/5ml 
19. Sodium Chloride infusion 0.9% 
20. Tetracycline eye ointment 1% 
[E]= Total No. of key drugs = (sum of A) [F] = sum of 
[G]= Ave. no. of stock out days = [F]/[E] D= 
Notes: 
[B] Go through the card covering the review period. Add the number of days that each of the key 
essential drugs is not available. A drug is considered in stock if it is or its equivalent is available 
in either generic or branded form. Indicate [B] the total number of days out of stock. 
The review should a 6-12 months period. If it is not possible then indicate the number of days 
covered by the review. 
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APPENDIX H: ACCURACY OF STOCK RECORDS I 
APPLICABLE TO HEALTH CENTRE II AND HEALTH CENTRE III 
(INDICATOR: % OF RECORDS THATCORRESPOND WITH PHYSICAL COUNTS) 
Survey Form No 8 
______________________ DATE __________________ _ FACILITY 
LOCATION ____________________ RESEARCHER ____________ __ 
Key drugs in stock to treat common conditions[A] '" CIJ E-
'" 
t: 
'Q:) :.0 Q) -a C C U ::l 'u -Q) '" 0 ::l ::l 0::: ~ 0 t: ell f- ._ u 0 U O'iii U "0 "0 "0 U ;>-. 




Z -"0 ~ "O..l: .... '" '" '" u .... o...l!l II 0 0 0 ::l . iii 8 -5 § '" u 0.. 0.. :.0- ;>-. Q) t: t: ..l: Q).- 0 Q) 
0::: ::J ::J <t:: 0.. 0::: ~ u >-
I. Amoxici II in capsules 2S0mg 
2.Acetysalicylic acid(aspirin)tablets 300mg 
3.Chloroquine tablets ISOmg base 
4. Cotrimoxazole tablets 480mg 
S. Ferrous sulphate/folic acid tablets 200mg/400mcg 
6. Mebendazole tablets 200mg 
7. Metronidazole tablets 200mg 
8. Retinol(vitamin A) capsule 100,000 [U 
9. Sulphadoxine/pyrimethamine tablets SOO/2S0mg 
10. Benzyl penicillin injection I g( I MU) 
II. Methylergometrine injection 200mcg/ml 
12. Gentamicin injection 40mg/ml 
13. Hydralazine injection 20mg/ml 
14. Magnesium sulphate injection SO% 
IS. Measles vaccine 
16. Medroxyprogesterone injection ISOmg/ml 
17. Benzoic acid + salicylic acid ointment 6%+3% 
18. Paracetamol syrup 120mg/Sml 
19. Oral rehydration salts(ORS) 
20. Tetracycline eye ointment 1% 
[B]= Total No. of records reviewed = __ [B] [C] 
[C]= Total No. of records that coincide with physical 
counts = 
--
[D]= % of records that coincide with physical counts 
= ---
Notes: 
I. [B] Sel ect I S stock records of any of the 20 key drugs listed. 
2. Adjust for un posted receipts and un posted issues where applicable. 
3. [D] % of records that coincide with physical counts = Total No. of Yes answers [CJ x 100 
Total number of records reviewed [B] 
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APPENDIX I: ACCURACY OF STOCK RECORDS II 
APPLICABLE TO HEALTH CENTRE IV AND DISTRICT HOSPITALS 
(INDICATOR: % OF RECORDS THA T CORRESPOND WITH PHYSICAL COUNTS) 
Survey Form No 9 
______________________ DATE __________________ _ FACILITY 
LOCATION ____________________ RESEARCHER~ __________ __ 
Key drugs in stock to treat common conditions[A] Vi I 
I OJ) ..... c.. I: 
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I. Amoxicillin capsules 2S0mg 
• 2. Ciprofloxacin tablets SOOmg 
• 3. Quinine sulfate tablets 300mg 
4. Cotrimoxazole tablets 480mg 
S. Ketoconazole tablets 200mg 
• 6. Mebendazole tablets 200mg 
• 7. Metronidazole tablets 200mg 
8. Lidocaine HCL injection 2% 
9. Quinine DI-HCL injection 600mg/2ml 
10. Ceftriaxone injection I g 
II. Methylergometrine injection 200mcg/ml 
12. Gentamicin injection 40mg/ml 
13. Hydralazine injection 20mg/ml 
14. Magnesium sulphate injection SO% 
IS. Cimetidine tablets 200mg 
16. Medroxyprogesterone injection ISOmg/ml 
17. Clotrimazole cream 1% 
18. Paracetamol syrup 120mg/Sml 
19. Sodium Chloride infusion 0.9% 
20. Tetracycline eye ointment 1% 
[B]= Total No. of records reviewed = [B] [C] 
I [C]= Total No. of records that coincide with physical 
• counts = -- --
[D]= % of records that coincide with physical counts 
= ---
Notes: 
I. [B] Select IS stock records of any of the 20 key drugs listed. 
2. Adjust for unposted receipts and unposted issues where applicable. 
3. [D] % of records that coincide with physical counts = Total No. of Yes answers [CJ x 100 
Total number of records reviewed [B] 
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APPENDIX J: INFORMED CONSENT FORM 
Dear Participant 
The study for which your participation is requested aims to evaluate the drug management 
at Public Health Facilities in Uganda. Inadequate access to essential drugs in public health 
facilities still remains a problem despite the increased budgetary allocation to drug 
procurement by the Ministry of Health. The study is for research purposes but the findings 
will contribute to the generation of knowledge base for policy makers to make well 
informed decisions so as to improve the drug management in the public health sector for 
the benefit of the entire nation. 
You will be requested to respond to questions during a face to face interview. Your 
answers to the questions and other information provided by you will only be used for the 
purpose of the research and your name will be used for authentication purposes only. You 
are assured that your identity and the information given will be treated with strict 
confidentiality. 
Your participation in this study is voluntary. You have the right to refuse to participate or 
withdraw from the study at any point. 
Declaration: 
I have read and understand the above information. I consent voluntarily to take part in this 
study as a participant and know that I have the right to withdraw from the study at any time 
without any consequences. 
(Name of participant) (Signature) 
Date: 
(DDMMYY) 
(Name of Researcher) (Signature) 
Date: 
(DDMMYY) 
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